Isoquinoline drug and use thereof in amelioration or treatment of gastrointestinal tumors

By designing 3,13-substituted berberine derivatives, the problems of drug resistance and side effects in the treatment of colorectal and gastric cancer have been solved, providing a novel antitumor drug with low toxicity and high efficacy for the improvement or treatment of colorectal and gastric cancer.

WO2026233446A1PCT designated stage Publication Date: 2026-11-12INST OF HEALTH & MEDICINE HEFEI COMPREHENSIVE NAT SCI CENT
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2026/095870
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-09
Filing Date
2026-05-09
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Treatment of colorectal and gastric cancer faces the problem of drug resistance. Existing drug treatments are not very effective and have significant side effects, making it difficult to achieve individualized treatment. In particular, immunotherapy has limited effectiveness for microsatellite stable colorectal cancer.

Method used

A 3,13-substituted berberine derivative compound is provided. By rationally designing and modifying the berberine structure, a novel antitumor drug with excellent inhibitory activity, low toxicity, and low likelihood of inducing drug resistance is developed. This drug is used to prepare pharmaceutical compositions for the treatment of colorectal cancer and gastric cancer.

Benefits of technology

This compound exhibits excellent inhibitory activity both in vivo and in vitro, and has good therapeutic effects on colon cancer and gastric cancer. It does not affect the growth of normal human cells, is not prone to drug resistance, and has the potential for synergistic effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN2026095870_12112026_PF_FP_ABST
    Figure CN2026095870_12112026_PF_FP_ABST
Patent Text Reader

Abstract

The present application relates to the technical field of small molecule drugs, and specifically relates to an isoquinoline drug and the use thereof in the amelioration or treatment of gastrointestinal tumors. An objective of the present application is to provide a compound, a pharmaceutical composition containing the compound and the use thereof in the treatment of colorectal cancer and gastric cancer. Provided in the present application is a 3,13-substituted berberine derivative. The drug itself has relatively low toxicity, does not affect the growth of normal human cells, and shows good application prospects in the development of new antitumor drugs, particularly drugs for resisting gastrointestinal tumors.
Need to check novelty before this filing date? Find Prior Art

Description

An isoquinoline drug and its application in improving or treating gastrointestinal tumors

[0001] Cross-referencing

[0002] This application claims priority to Chinese Patent Application No. 202510593023.6, filed on May 9, 2025, entitled “An isoquinoline drug and its application in improving or treating gastrointestinal tumors,” the entire disclosure of which is incorporated herein by reference. Technical Field

[0003] This application relates to the field of small molecule drug technology, specifically to an isoquinoline drug and its application in improving or treating gastrointestinal tumors. Background Technology

[0004] Colorectal cancer, also known as colon cancer, is one of the most common malignant tumors worldwide. According to data from the World Health Organization (WHO), the incidence and mortality rates of colorectal cancer have been on the rise in recent years, especially in developed countries. The danger of colorectal cancer is mainly reflected in its high incidence and mortality rates. In recent years, the prevalence and mortality rates of colorectal cancer have continued to rise globally. The high incidence and mortality rates of colorectal cancer make it a significant global public health issue.

[0005] Despite progress in the diagnosis and treatment of colorectal cancer, several challenges remain. First, early diagnosis rates are low, with many patients diagnosed at middle or late stages, missing the optimal treatment window. Second, colorectal cancer exhibits high heterogeneity, with significant differences in tumor biology among patients, leading to inconsistent treatment outcomes. Furthermore, drug resistance is a prominent issue in colorectal cancer, with many patients developing resistance during treatment, resulting in poor treatment outcomes.

[0006] Currently, drug treatment for colorectal cancer mainly includes chemotherapy, targeted therapy, and immunotherapy. Chemotherapy is the foundation of colorectal cancer treatment, and commonly used chemotherapy drugs include 5-fluorouracil (5-FU), oxaliplatin, and irinotecan. Targeted therapy is an important advancement in colorectal cancer treatment in recent years, and commonly used targeted drugs include anti-EGFR antibodies (such as cetuximab) and anti-VEGF antibodies (such as bevacizumab). Immunotherapy is an emerging field in colorectal cancer treatment, especially PD-1 / PD-L1 inhibitors, which have shown good efficacy in colorectal cancer patients with high microsatellite instability (MSI-H).

[0007] Despite progress in drug treatment for colorectal cancer, several challenges remain. First, drug resistance is a significant issue, with many patients developing resistance during treatment, leading to poor outcomes. Second, the application of targeted therapy and immunotherapy is limited, applicable only to a subset of patients. Furthermore, drug treatments often have substantial side effects, impacting patients' quality of life. Therefore, improving the efficacy of drug treatments, reducing side effects, and expanding their application are the main challenges currently facing colorectal cancer treatment.

[0008] Currently, chemotherapy drugs for gastric cancer include fluorouracil (5-FU), platinum-based drugs (cisplatin, oxaliplatin), and taxanes (docetaxel) as basic regimens. However, these regimens suffer from serious drug resistance (approximately 50% of patients do not respond), myelosuppression, and neurotoxicity. Furthermore, targeted therapy and immunotherapy have low response rates, and chemotherapy and targeted therapies are prone to failure due to tumor heterogeneity, compensatory activation of signaling pathways, and other mechanisms. Most patients also lack targetable driver gene mutations.

[0009] Meanwhile, the severe side effects of traditional chemotherapy (such as bone marrow suppression and gastrointestinal reactions) affect treatment adherence, necessitating breakthrough therapies. The development of small molecule drugs for gastric cancer needs to focus on three core needs: overcoming drug resistance, improving precision, and reducing toxicity.

[0010] Application content

[0011] This application aims to at least partially address one of the technical problems in the related art. Therefore, one objective of this application is to provide a compound, a pharmaceutical composition comprising said compound, and its use in treating gastrointestinal tumors. This application provides a 3,13-substituted berberine derivative, which itself has low toxicity, does not affect the growth of normal human cells, and shows great promise in the development of novel antitumor drugs, especially in the development of drugs for treating drug-resistant colon and gastric cancer.

[0012] Therefore, the first aspect of this application provides a compound, said compound being a compound of general formula (I) or a stereoisomer, tautomer, hydrate, solvate, pharmaceutically acceptable salt, or prodrug of a compound of general formula (I):

[0013] in,

[0014] R1 and R2 are each independently selected from -(CH2)mR3, -(CH2)n-CN, unsubstituted or substituted with at least one Ra group of the following groups: C1-C20 alkyl, C2-C20 alkenyl, C2-C20 alkynyl;

[0015] m = 1 ~ 10, n = 1 ~ 10,

[0016] R3 is a 3-10 membered heterocyclic group, C6-C20 aryl group, or 5-20 membered heteroaryl group that is unsubstituted or substituted with at least one Rb.

[0017] Ra and Rb are each independently selected from -NH2, -NO2, halogen, C1-C20 alkoxy, C1-C20 alkyl, C2-C20 alkenyl, and C2-C20 alkynyl.

[0018] The most serious problem in the treatment of colorectal and gastric cancer is widespread drug resistance. The number of chemotherapy drugs applicable to these cancers is extremely limited. More seriously, tumor cells easily develop resistance to chemotherapy drugs (such as 5-fluorouracil and oxaliplatin) and targeted therapies (such as anti-EGFR and anti-VEGF), leading to decreased or ineffective treatment. Furthermore, chemotherapy and targeted therapies are often accompanied by serious side effects, such as myelosuppression and neurotoxicity, affecting patients' quality of life and even limiting the continuation of treatment. In addition, immunotherapy has significant limitations in the treatment of colorectal and gastric cancer. Immune checkpoint inhibitors have limited effectiveness against microsatellite stable (MSS) colorectal cancer and may cause immune-related side effects. Moreover, the high cost of targeted drugs and immunotherapy makes them unaffordable for some patients, affecting treatment accessibility.

[0019] The compound represented by general formula (I) of this application can be used to prepare drugs for treating colon cancer and gastric cancer, which exhibit excellent inhibitory activity both in vivo and in vitro. Moreover, the drug itself has low toxicity, does not affect the growth of normal human cells, and is not prone to inducing drug resistance, showing great promise for the development of novel antitumor drugs, especially for the development of drugs against drug-resistant colon cancer.

[0020] According to the embodiments of this application, in the compound shown in general formula (I), R1 and R2 are each independently selected from -(CH2)mR3, -(CH2)n-CN, unsubstituted or substituted with at least one Ra group of the following groups: C1-C15 alkyl, C2-C15 alkenyl, C2-C15 alkynyl;

[0021] m = 1 ~ 10, n = 1 ~ 10,

[0022] R3 is an unsubstituted or substituted C6-C20 aryl or 5-20 heteroaryl group with at least one Rb substitution;

[0023] Ra and Rb are each independently selected from -NH2, -NO2, halogen, C1-C15 alkoxy, C1-C15 alkyl, C2-C15 alkenyl, and C2-C15 alkynyl.

[0024] According to the embodiments of this application, in the compound shown in general formula (I), R1 and R2 are each independently selected from -(CH2)mR3, -(CH2)n-CN, unsubstituted or substituted with at least one Ra group of the following groups: C1-C15 alkyl, C2-C15 alkenyl, C2-C15 alkynyl;

[0025] m = 1~5, n = 1~10

[0026] R3 is an unsubstituted or C6-C20 aryl group substituted with at least one Rb;

[0027] Ra and Rb are each independently selected from -NH2, -NO2, halogen, C1-C10 alkoxy, C1-C10 alkyl, C2-C10 alkenyl, and C2-C10 alkynyl.

[0028] According to the embodiments of this application, in the compound shown in general formula (I), R1 and R2 are each independently selected from -(CH2)mR3, -(CH2)n-CN, unsubstituted or substituted with at least one Ra group of the following groups: C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl;

[0029] m = 1~5, n = 1~10

[0030] R3 is an unsubstituted or phenyl group substituted with at least one Rb;

[0031] Ra and Rb are each independently selected from -NH2, -NO2, halogen, C1-C10 alkoxy, C1-C10 alkyl, C2-C10 alkenyl, and C2-C10 alkynyl.

[0032] According to embodiments of this application, Ra and Rb are each independently selected from -NH2, -NO2, halogen, C1-C10 alkoxy, and C1-C10 alkyl.

[0033] According to an embodiment of this application, Ra is -NH2;

[0034] Rb is selected from -NO2, halogens, C1-C10 alkoxy groups, and C1-C10 alkyl groups.

[0035] According to the embodiments of this application, in the compound shown in general formula (I), R1 and R2 are each independently selected from -(CH2)mR3, -(CH2)n-CN, unsubstituted C2-C10 alkenyl, unsubstituted C2-C10 alkynyl, unsubstituted or substituted with at least one Ra alkyl group.

[0036] m = 1~5, n = 1~10

[0037] R3 is an unsubstituted or phenyl group substituted with at least one Rb;

[0038] Ra is -NH2;

[0039] Rb is selected from -NO2, halogens, C1-C10 alkoxy groups, and C1-C10 alkyl groups.

[0040] According to embodiments of this application, the compound is selected from one of the following structures:

[0041] A second aspect of this application provides a pharmaceutical composition. According to embodiments of this application, the pharmaceutical composition comprises the compound described in the first aspect.

[0042] According to embodiments of this application, the pharmaceutical composition further includes pharmaceutically acceptable excipients, such as pharmaceutically acceptable carriers, diluents, or excipients.

[0043] The compounds provided in this application are used to prepare pharmaceutical products in various dosage forms, which are then administered to subjects at therapeutically effective amounts. After being absorbed by the subjects, the pharmaceutical products can treat or improve colorectal cancer.

[0044] According to embodiments of this application, the pharmaceutical composition further comprises one or more other therapeutic agents. These other therapeutic agents have similar functions to the compounds of this application and can all be used to treat or improve colorectal cancer.

[0045] This application relates to suitable pharmaceutically acceptable salts of compounds of general formula (I) or (I), including but not limited to hydrochlorides, hydrobromicates, sulfates or hydrogen sulfates, phosphates or hydrogen phosphates, acetates, benzoates, succinates, fumarates, maleates, lactates, citrates, tartrates, gluconates, methanesulfonates, benzenesulfonates, or p-toluenesulfonates. As stated above, any compound of this application mentioned herein includes its pharmaceutically acceptable salt, solvate, or combination thereof.

[0046] In addition to pharmaceutically acceptable salts of the compounds of this application, this application also includes other salts. These may serve as intermediates in the purification of the compounds or in the preparation of other pharmaceutically acceptable salts, or may be used for the identification, characterization, or purification of the compounds of this application.

[0047] The third aspect of this application provides the use of the compounds described in the first aspect in the preparation of a medicament for treating gastrointestinal tumors.

[0048] According to embodiments of this application, the digestive tract tumor includes colorectal cancer and gastric cancer.

[0049] The 3,13-substituted berberine derivatives provided in this application have a completely different mechanism of action from commonly used anti-colorectal and gastric cancer drugs in clinical practice, and may play a superior role against drug-resistant colorectal and gastric cancer. The 3,13-substituted berberine derivatives of this application are expected to produce synergistic effects when combined with other first-line anti-colorectal and gastric cancer drugs.

[0050] Additional aspects and advantages of this application will be set forth in part in the description which follows, and in part will be obvious from the description, or may be learned by practice of this application. Attached Figure Description

[0051] The above and / or additional aspects and advantages of this application will become apparent and readily understood from the description of the embodiments taken in conjunction with the following drawings, in which:

[0052] Figure 1 shows the inhibitory activity curves of the candidate compound MX51 against three colon cancer cell lines SW620, DLD-1, and SW480, and the corresponding half-maximal inhibitory concentrations (IC50). In Figure 1, A shows the IC50 of compound MX51 against SW620 cell line; B shows the IC50 of compound MX51 against DLD-1 cell line; and C shows the IC50 of compound MX51 against SW480 cell line.

[0053] Figure 2 is an evaluation of the effect of MX51 on inhibiting the occurrence and development of colon cancer in subcutaneous tumor model, orthotopic cecal inoculation model and AOM / DSS spontaneous colon cancer model; among them, DMSO was set as the control group, A is a line graph of the effect of MX51 on tumor volume, and B is a bar graph of the effect of MX51 on tumor weight.

[0054] Figure 3 shows the effect of MX51 on tumor inhibition in the cecum of immunodeficient mice in situ; DMSO was set as the control group. A is the cecum after treatment with or without MX51 (top); B is the mouse count corresponding to different tumor volumes; C is the mouse count corresponding to different tumor weights; D is the mouse survival rate line graph.

[0055] Figure 4 shows the in vivo activity evaluation of MX51 in BALb / c mice modeled with azomethane (AOM) (10 mg / mL); DMSO was set as a control group. A is a schematic diagram of in vivo drug administration time, B is a diagram of the effect of MX51 treatment on mouse body weight, C is a diagram of colon tumor distribution, D is a diagram of colon length counting, E is a diagram of colon HE staining (left) and polyp count bar chart (right), and F is a line graph of mouse survival rate. Detailed Implementation

[0056] The embodiments of this application are described in detail below. The embodiments described below are exemplary and are only used to explain this application, and should not be construed as limiting this application.

[0057] It should be noted that the terms "first" and "second" are used for descriptive purposes only and should not be construed as indicating or implying relative importance or implicitly specifying the number of technical features indicated. Therefore, a feature defined as "first" or "second" may explicitly or implicitly include one or more of that feature. Furthermore, in the description of this application, unless otherwise stated, "multiple" means two or more.

[0058] The endpoints and any values ​​of the ranges disclosed herein are not limited to the precise ranges or values, and these ranges or values ​​should be understood to include values ​​close to these ranges or values. For numerical ranges, the endpoint values ​​of the various ranges, the endpoint values ​​of the various ranges and individual point values, and individual point values ​​can be combined with each other to obtain one or more new numerical ranges, which should be considered as specifically disclosed herein.

[0059] To facilitate understanding of this application, certain technical and scientific terms are specifically defined below. Unless otherwise expressly defined elsewhere in this document, all other technical and scientific terms used herein have the meanings commonly understood by one of ordinary skill in the art to which this application pertains.

[0060] In this document, the terms “comprising” or “including” are open-ended expressions, meaning that they include the contents specified in this application but do not exclude other contents.

[0061] In this document, the terms “optionally,” “optionally,” or “optionally” generally refer to an event or condition that may, but may not, occur, and the description includes both cases in which the event or condition occurs and cases in which the event or condition does not occur.

[0062] Unless otherwise stated, the definitions of groups and terms recorded in this application specification and claims, including their definitions as examples, exemplary definitions, preferred definitions, definitions recorded in tables, and definitions of specific compounds in the examples, can be arbitrarily combined and combined with each other. Such combinations and combinations of group definitions and compound structures shall fall within the scope of this application specification.

[0063] The term "pharmaceutically acceptable salt" refers to a pharmaceutically acceptable, non-toxic salt of an acid or base, including salts of inorganic acids and bases, and salts of organic acids and bases. Salts derived from inorganic bases include, but are not limited to, metal salts formed from Al, Ca, Li, Mg, K, Na, and Zn; salts derived from organic bases include, but are not limited to, salts of primary, secondary, or tertiary amines, including naturally occurring substituted or unsubstituted amines, cyclic amines, and basic ion exchange resins such as ammonium, isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, diethanolamine, ethanolamine, dimethylethanolamine, 2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, caffeine, procaine, choline, betaine, penicillin, ethylenediamine, glucosamine, methylglucosamine, theobromine, triethanolamine, tromethamine, purine, piperazine, piperidine, N-ethylpiperidine, or polyamine resins. Organic salts derived from inorganic and organic acids, including but not limited to those formed from sulfuric acid, phosphoric acid, nitric acid, hydrobromic acid, hydrochloric acid, formic acid, acetic acid, propionic acid, benzenesulfonic acid, benzoic acid, phenylacetic acid, salicylic acid, alginic acid, aminoanilic acid, camphoric acid, citric acid, vinyl sulfonic acid, formic acid, fumaric acid, furoic acid, gluconic acid, glucuronic acid, glutamic acid, glycolic acid, hydroxyethanesulfonic acid, lactic acid, maleic acid, malic acid, mandelic acid, mucilage, dihydroxynaphthyl acid, pantothenic acid, stearic acid, succinic acid, sulfanilic acid, tartaric acid, p-toluenesulfonic acid, malonic acid, 2-hydroxypropionic acid, oxalic acid, glycolic acid, galacturonic acid, citric acid, lysine, arginine, aspartic acid, cinnamic acid, methanesulfonic acid, ethanesulfonic acid, or trifluoromethanesulfonic acid.

[0064] The term "stereoisomer" refers to isomers that are produced by different spatial arrangements of atoms in a molecule, including cis-trans isomers, enantiomers, diastereomers, and conformational isomers.

[0065] The term "tautomer" refers to a functional group isomer resulting from the rapid movement of an atom between two positions within a molecule. The compounds in this application exhibit tautomerism. Tautomers can exist in two or more interconvertible forms. Proton-shift tautomers arise from the migration of covalently bonded hydrogen atoms between two atoms. Tautomers generally exist in equilibrium; attempts to isolate a single tautomer typically yield a mixture whose physicochemical properties are consistent with those of the mixture of compounds. The equilibrium position depends on the intramolecular chemical characteristics. For example, in many aliphatic aldehydes and ketones such as acetaldehyde, the ketone form is dominant; while in phenols, the enol form is dominant. This application encompasses all tautomeric forms of the compounds.

[0066] The term "pharmaceutical composition" refers to a mixture of one or more compounds described in this application or their physiologically / pharmaceutical acceptable salts or prodrugs with other chemical components, such as physiologically / pharmaceutical acceptable carriers and excipients. The purpose of a pharmaceutical composition is to facilitate administration of the compound to a living organism, thereby promoting the absorption of the active ingredient and enabling it to exert its biological activity.

[0067] The term "solvent" refers to a compound or salt thereof of this application comprising a stoichiometric or nonstoichiometric solvent bound by intermolecular noncovalent forces, and a hydrate when the solvent is water.

[0068] The term "prodrug" refers to a compound of this application that can be converted into a biologically active form under physiological conditions or through solvation. The prodrug of this application is prepared by modifying a functional group in the compound; this modification can be performed conventionally or removed in vivo to obtain the parent compound.

[0069] The term “C1-C10 alkyl” should be understood to mean a straight-chain or branched saturated monovalent hydrocarbon group having 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms. The alkyl group is, for example, methyl, ethyl, n-propyl, n-butyl, n-pentyl, n-hexyl, isopropyl, isobutyl, sec-butyl, tert-butyl, isopentyl, 2-methylbutyl, 1-methylbutyl, 1-ethylpropyl, 1,2-dimethylpropyl, neopentyl, 1,1-dimethylpropyl, 4-methylpentyl, 3-methylpentyl, 2-methylpentyl, 1-methylpentyl, 2-ethylbutyl, 1-ethylbutyl, 3,3-dimethylbutyl, 2,2-dimethylbutyl, 1,1-dimethylbutyl, 2,3-dimethylbutyl, 1,3-dimethylbutyl, or 1,2-dimethylbutyl, etc.; "C1-C6 alkyl" should be understood to mean a straight-chain or branched saturated monovalent hydrocarbon group having 1, 2, 3, 4, 5, or 6 carbon atoms.

[0070] The term “C2-C20 alkynyl” should be understood to preferably represent a straight-chain or branched monovalent hydrocarbon group containing one or more triple bonds and having 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 carbon atoms.

[0071] The term “C2-C20 alkenyl” should be understood to preferably represent a straight-chain or branched monovalent hydrocarbon group containing one or more double bonds and having 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 carbon atoms.

[0072] The term "3-10 membered heterocyclic group" refers to a saturated monovalent monocyclic or bicyclic hydrocarbon ring containing 1-5, preferably 1-3, heteroatoms selected from N, O, and S. Specifically, the heterocyclic group may include, but is not limited to: 4-membered rings, such as azirmonobutylene and oxobutylene; 5-membered rings, such as tetrahydrofuranyl, dioxacyclopentenyl, pyrrolyl, imidazoalkyl, pyrazolyl, or pyrrololinyl; or 6-membered rings, such as tetrahydropyranyl, piperidinyl, morpholinyl, dithiaalkyl, thiomorpholinyl, piperazinyl, or trithiaalkyl; or 7-membered rings, such as diazacycloheptyl. Optionally, the heterocyclic group may be benzofused. The heterocyclic group may be bicyclic, such as, but not limited to, a 5,5-membered ring, like a hexahydrocyclopentano[c]pyrrole-2(1H)-yl ring, or a 5,6-membered bicyclic ring, such as a hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl ring. The nitrogen-containing ring may be partially unsaturated, i.e., it may contain one or more double bonds, such as, but not limited to, 2,5-dihydro-1H-pyrrole, 4H-[1,3,4]thiadiazinyl, 4,5-dihydrooxazolyl, or 4H-[1,4]thiazinyl, or it may be benzofused, such as, but not limited to, dihydroisoquinolinyl. According to this application, the heterocyclic group is non-aromatic.

[0073] The term "C6-C20 aryl" should be understood to preferably refer to a monocyclic, bicyclic, or tricyclic hydrocarbon ring having 6-20 carbon atoms and exhibiting monovalent aromatic or partially aromatic properties. In particular, it refers to a ring having 6 carbon atoms ("C6 aryl"), such as phenyl; or a ring having 9 carbon atoms ("C9 aryl"), such as indenyl or indenyl; or a ring having 10 carbon atoms ("C10 aryl"), such as tetrahydronaphthyl, dihydronaphthyl, or naphthyl; or a ring having 13 carbon atoms ("C13 aryl"), such as fluorenyl; or a ring having 14 carbon atoms ("C14 aryl"), such as anthraceneyl.

[0074] The term "5-20-membered heteroaryl" should be understood to include monovalent monocyclic, bicyclic, or tricyclic aromatic ring systems having 5-20 ring atoms and containing 1-5 heteroatoms independently selected from N, O, and S, such as "5-14-membered heteroaryl". The term "5-14-membered heteroaryl" should also be understood to include monovalent monocyclic, bicyclic, or tricyclic aromatic ring systems having 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14 ring atoms, particularly 5, 6, 9, or 10 carbon atoms, and containing 1-5, preferably 1-3, heteroatoms each independently selected from N, O, and S, and in each case, may be benzofused. Specifically, the heteroaryl group is selected from thienyl, furanyl, pyrroleyl, oxazolyl, thiazolyl, imidazoleyl, pyrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazolyl, thiadiazolyl, thia-4H-pyrazolyl, and their benzo[derivatives], such as benzofuranyl, benzothienyl, benzooxazolyl, benzoisooxazolyl, benzoimidazolyl, benzotriazolyl, indazole, indolyl, isindolyl, etc.; or pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, and their benzo[derivatives], such as quinolinyl, quinazolinyl, isoquinolinyl, etc.; or acrylinyl, inazinyl, purinyl, and their benzo[derivatives]; or terpenolyl, phthalazinyl, quinazolinyl, quinoxolinyl, naphridinyl, pteridinyl, carbazolyl, acridineyl, phenazinyl, phenothiazinyl, phenothiazinyl, etc.

[0075] The term "excipient" refers to a pharmaceutically acceptable inert ingredient. Non-limiting examples of the types of "excipients" include binders, disintegrants, lubricants, flow aids, stabilizers, fillers, and diluents. Excipients enhance the handling properties of pharmaceutical formulations by increasing flowability and / or adhesion, making the formulation more suitable for direct compression. Typical examples of pharmaceutically acceptable carriers suitable for the above formulations include: sugars, such as lactose, sucrose, mannitol, and sorbitol, or corn starch, tapioca starch, and potato starch; cellulose and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose, and methyl cellulose; calcium phosphates, such as dicalcium phosphate and tricalcium phosphate; sodium sulfate; calcium sulfate; polyvinylpyrrolidone; polyvinyl alcohol; stearic acid; alkaline earth metal stearates, such as magnesium stearate and calcium stearate; vegetable oils, such as peanut oil, cottonseed oil, sesame oil, olive oil, and corn oil; nonionic, cationic, and anionic surfactants; ethylene glycol polymers; fatty alcohols; and hydrolyzed cereal solids and other nontoxic, compatible excipients commonly used in pharmaceutical formulations, such as fillers, binders, disintegrants, buffers, preservatives, antioxidants, lubricants, and colorants.

[0076] Colorectal cancer is one of the most common malignant tumors worldwide, with its incidence and mortality rates on the rise. Despite some progress in diagnosis and treatment, many challenges remain. Early diagnosis, personalized treatment, overcoming drug resistance, and reducing side effects are the main directions of current colorectal cancer treatment. Future research should focus on exploring new therapeutic targets, developing new drugs, and optimizing treatment regimens to improve the survival rate and quality of life of colorectal cancer patients.

[0077] Berberine (BBR) is an isoquinoline alkaloid mainly found in traditional Chinese medicinal plants such as Coptis chinensis and Phellodendron amurense. Its chemical structure is that of a quaternary ammonium salt, possessing a planar aromatic ring and multiple oxygen atoms, which endow it with excellent biological activities, such as antibacterial, anti-inflammatory, and antitumor effects.

[0078] Studies have shown that berberine exerts its anti-colon cancer effects by inhibiting cancer cell proliferation, inducing apoptosis, inhibiting metastasis and angiogenesis, and regulating gut microbiota. Furthermore, berberine possesses advantages such as multi-target action, low toxicity and safety, synergistic effects, reversal of drug resistance, and improved bioavailability. Research indicates that in phase II clinical trials, adjuvant berberine therapy prolonged progression-free survival by 2-3 months. However, the anti-colon tumor activity of berberine needs further investigation, and its mechanism remains unclear.

[0079] To address the aforementioned shortcomings of existing technologies, the purpose of this application is to provide a class of 3,13-substituted berberine derivatives, their preparation methods, and applications. Through the rational design and modification of berberine (BBR), candidate drugs with improved activity, novel mechanisms, low likelihood of inducing drug resistance, and good safety are obtained.

[0080] According to a specific embodiment of this application, this application provides a 3,13-substituted berberine derivative, the structural formula of which is shown in general formula (I):

[0081] in,

[0082] R1 and R2 are each independently selected from -(CH2)mR3, -(CH2)n-CN, unsubstituted or substituted with at least one Ra group of the following groups: C1-C20 alkyl, C2-C20 alkenyl, C2-C20 alkynyl;

[0083] m = 1 ~ 10, n = 1 ~ 10,

[0084] R3 is a 3-10 membered heterocyclic group, C6-C20 aryl group, or 5-20 membered heteroaryl group that is unsubstituted or substituted with at least one Rb.

[0085] Ra and Rb are each independently selected from -NH2, -NO2, halogen, C1-C20 alkoxy, C1-C20 alkyl, C2-C20 alkenyl, and C2-C20 alkynyl.

[0086] It should be noted that m can be 1, 2, 3, 4, 5, 6, 7, 8, 9, 10; n can be 1, 2, 3, 4, 5, 6, 7, 8, 9, 10. For example, m can be 1-3, 1-4, 1-5, 1-6, 1-7, 1-8, 1-9 or 1-10, and n can be 1-3, 1-4, 1-5, 1-6, 1-7, 1-8, 1-9 or 1-10.

[0087] According to a specific embodiment of this application, in the compound shown in general formula (I), R1 and R2 are each independently selected from -(CH2)mR3, -(CH2)n-CN, unsubstituted or substituted with at least one Ra group of the following groups: C1-C15 alkyl, C2-C15 alkenyl, C2-C15 alkynyl;

[0088] m = 1 ~ 10, n = 1 ~ 10,

[0089] R3 is an unsubstituted or substituted C6-C20 aryl or 5-20 heteroaryl group with at least one Rb substitution;

[0090] Ra and Rb are each independently selected from -NH2, -NO2, halogen, C1-C15 alkoxy, C1-C15 alkyl, C2-C15 alkenyl, and C2-C15 alkynyl.

[0091] According to a specific embodiment of this application, in the compound shown in general formula (I), R1 and R2 are each independently selected from -(CH2)mR3, -(CH2)n-CN, unsubstituted or substituted with at least one Ra group of the following groups: C1-C15 alkyl, C2-C15 alkenyl, C2-C15 alkynyl;

[0092] m = 1~5, n = 1~10

[0093] R3 is an unsubstituted or C6-C20 aryl group substituted with at least one Rb;

[0094] Ra and Rb are each independently selected from -NH2, -NO2, halogen, C1-C10 alkoxy, C1-C10 alkyl, C2-C10 alkenyl, and C2-C10 alkynyl.

[0095] According to a specific embodiment of this application, in the compound shown in general formula (I), R1 and R2 are each independently selected from -(CH2)mR3, -(CH2)n-CN, unsubstituted or substituted with at least one Ra group of the following groups: C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl;

[0096] m = 1~5, n = 1~10

[0097] R3 is an unsubstituted or phenyl group substituted with at least one Rb;

[0098] Ra and Rb are each independently selected from -NH2, -NO2, halogen, C1-C10 alkoxy, C1-C10 alkyl, C2-C10 alkenyl, and C2-C10 alkynyl.

[0099] According to a specific embodiment of this application, Ra and Rb are each independently selected from -NH2, -NO2, halogen, C1-C10 alkoxy, and C1-C10 alkyl.

[0100] According to a preferred embodiment of this application, Ra is -NH2;

[0101] Rb is selected from -NO2, halogens, C1-C5 alkoxy groups, and C1-C5 alkyl groups. Among them, halogens are fluorine, chlorine, bromine, and iodine.

[0102] According to a specific embodiment of this application, this application provides a method for preparing a 3,13-substituted berberine derivative, comprising the following steps:

[0103] The intermediate (M1), anhydrous acetonitrile, potassium carbonate, and the first raw material were reacted at 60–70 °C, with the reaction progress monitored by TLC. After the reaction was complete, the mixture was cooled until a solid completely precipitated, filtered, and the filtrate was mixed with silica gel. Using dichloromethane and methanol as the mobile phase, the mixture was purified by Flash column chromatography to obtain a yellow intermediate (M2). The obtained intermediate was then reacted with anhydrous acetonitrile, sodium hydride, and the second raw material at 70–90 °C, with the reaction progress monitored by TLC. After the reaction was complete, the mixture was neutralized with hydrochloric acid and methanol solution, mixed with silica gel, and again purified by Flash column chromatography using dichloromethane and methanol as the mobile phase to obtain a yellow final product.

[0104] According to a specific embodiment of this application, this application provides the use of the aforementioned 3,13-substituted berberine derivatives or physiologically acceptable salts or pharmaceutical compositions in the preparation of products for the prevention and / or treatment of colorectal cancer.

[0105] According to a specific embodiment of this application, this application provides the use of the aforementioned 3,13-substituted berberine derivatives or physiologically acceptable salts or pharmaceutical compositions in the preparation of medicaments for the prevention and / or treatment of colon cancer.

[0106] This application provides a class of 3,13-substituted berberine derivatives of general formula (I), their preparation methods, and applications. Previous work specifically screened compounds that are highly effective, low in toxicity, and unlikely to induce drug resistance. Compared to BBR, the 3,13-substituted berberine derivatives provided in this application exhibit more promising inhibitory activity against three colon cancer cell lines. The effects of the 3,13-substituted berberine derivatives on tumor volume and mass were investigated in mice with ectopic and in situ tumors. The results showed that the 3,13-substituted berberine derivatives significantly inhibited the growth of SW620 tumors and prolonged the survival of these tumor-bearing mice. Furthermore, in mice modeled with azomethane (AOM) (10 mg / mL), the 3,13-substituted berberine derivatives significantly reduced tumor number, prolonged total cecal length, reduced intestinal mucosal barrier damage, and prolonged mouse survival without affecting mouse body weight. This has promising applications in the development of novel anti-colon cancer drugs, especially in the development of treatments for drug-resistant colon cancer.

[0107] It should be noted that the use of the 3,13-substituted berberine derivatives shown in general formula (I) in the preparation of drugs for treating colon cancer and gastric cancer, as well as in the preparation, prevention and / or treatment of colon cancer and gastric cancer, should all be within the scope of protection of this application.

[0108] The present disclosure will be explained below with reference to embodiments. Those skilled in the art will understand that the following embodiments are for illustrative purposes only and should not be construed as limiting the scope of the disclosure. Where specific techniques or conditions are not specified in the embodiments, they are performed in accordance with the techniques or conditions described in the literature in the art or according to the product instructions. Reagents or instruments whose manufacturers are not specified are all conventional products that can be obtained commercially.

[0109] Example 1 Synthesis of 2,9,10-trimethoxy-13-(3-methylbut-2-en-1-yl)-3-((3-nitrobenzyl)oxy)-5,6-dihydroisoquino[3,2-a]isoquinoline-7-onium (MX1)

[0110] M1, anhydrous acetonitrile, potassium carbonate, and m-nitrobenzyl bromide (first raw material) were reacted at 65°C. The reaction progress was monitored by TLC. After the reaction was complete, the mixture was cooled until the solid completely precipitated, filtered, and the filtrate was mixed with silica gel. Using dichloromethane and methanol as the mobile phase, the mixture was purified by Flash column chromatography to obtain a yellow intermediate. The obtained intermediate was then reacted with anhydrous acetonitrile, sodium hydride, and 3,3-dimethylallyl bromide (second raw material) at 85°C. The reaction progress was monitored by TLC. After the reaction was complete, the mixture was neutralized with hydrochloric acid and methanol solution, and then mixed with silica gel. Again using dichloromethane and methanol as the mobile phase, the mixture was purified by Flash column chromatography to obtain the yellow final product MX1. The NMR results of the final product are as follows:

[0111] 1 H NMR(500MHz,DMSO-d6)δ9.94(s,1H),8.29(tt,J=2.3,1.0Hz,1H),8.17(ddd,J=8.8,2.3,1.2Hz,1H),7.72(ddq,J =8.1,2.2,1.2Hz,1H),7.61(dd,J=8.8,7.8Hz,1H),7.39(d,J=8.5Hz,1H),7.32(s,1H),7.19(d,J=8.8Hz,1H),7. 04(t,J=1.1Hz,1H),5.31(dddd,J=9.1,7.3,3.3,1.6Hz,1H),5.24(t,J=1.0Hz,2H),4.64(dddd,J=7.3,4.6,1.7Hz ,2H),4.02(s,3H),3.88(d,J=13.9Hz,5H),3.46(dp,J=7.4,1.0Hz,2H),3.21–3.14(m,2H),1.68(q,J=1.2Hz,6H).

[0112] 13 C NMR (125MHz, DMSO-d6) δ150.60,149.86,149.48,148.45,147.22,142.90,137.02,136.89,133.35,130.41,130.17,129.75,129.26,128.59 ,124.37,123.79,123.77,122.76,122.09,121.57,120.78,114.29,11 1.38,71.22,61.81,58.10,56.30,55.65,28.68,27.97,24.49,19.28.

[0113] ESI + :541.62.

[0114] Example 2 Synthesis of 13-hexyl-2,9,10-trimethoxy-3-((3-nitrobenzyl)oxy)-5,6-dihydroisoquino[3,2-a]isoquinoline-7-onium (MX2)

[0115] The experimental procedure was the same as in Example 1, except that the first raw material was m-nitrobenzyl bromide and the second raw material was 1-bromo-n-pentanamine; the NMR results of the final product are as follows:

[0116] 1H NMR (500MHz, DMSO-d6) δ9.94(s,1H),8.29(tt,J=2.2,1.0Hz,1H),8.17(ddd,J=8.8,2.3,1.2Hz,1H),7.72(dtd,J =8.2,2.4,1.2Hz,1H),7.61(dd,J=8.8,7.8Hz,1H),7.35–7.30(m,2H),7.19(d,J=8.5Hz,1H),7.04(t,J=1.0Hz,1 H),5.24(t,J=1.0Hz,2H),4.63(ddd,J=7.6,4.9,1.2Hz,2H),4.02(s,3H),3.88(d,J=13.9Hz,5H),3.21–3.14(m, 2H),2.81–2.72(m,4H),1.87(t,J=6.5Hz,2H),1.65(tt,J=8.3,7.4Hz,2H),1.56–1.47(m,2H),1.41–1.32(m,2H).

[0117] 13 C NMR (125MHz, DMSO-d6) δ150.63,149.86,149.48,148.45,146.81,143.03,137.45,137.02,135.28,133.35,133.19,130.30,129.26,124.3 7,123.79,123.25,122.15,121.99,121.50,114.25,111.38,71.22,6 1.81,58.81,56.30,55.65,40.93,32.65,30.59,28.66,27.97,26.74.

[0118] ESI + :558.65.

[0119] Example 3 Synthesis of 13-Butyl-2,9,10-trimethoxy-3-((2-nitrobenzyl)oxy)-5,6-dihydroisoquino[3,2-a]isoquinoline-7-onium (MX3)

[0120] The experimental procedure was the same as in Example 1, except that the first raw material was o-nitrobenzyl bromide and the second raw material was 1-bromobutane; the NMR results of the final product are as follows:

[0121] 1H NMR (500MHz, DMSO-d6) δ9.94 (s, 1H), 8.08 (dd, J=8.6, 1.4Hz, 1H), 7.63 (td, J=7.3, 1.2Hz, 1H), 7.60–7. 54(m,1H),7.51(dq,J=7.2,1.1Hz,1H),7.35–7.30(m,2H),7.19(d,J=8.5Hz,1H),7.04(t,J=1.0Hz,1H), 5.41(d,J=1.0Hz,2H),4.63(ddd,J=7.6,4.9,1.2Hz,2H),4.02(s,3H),3.88(d,J=13.9Hz,5H),3.21–3. 14(m,2H),2.87–2.70(m,2H),1.65(tt,J=8.9,6.6Hz,2H),1.36(h,J=6.9Hz,2H),0.93(t,J=7.2Hz,3H).

[0122] 13 C NMR(125MHz,DMSO-d6)δ150.63,149.90,149.51,146.88,146.81,143.03,137.43,135.15,133.18,131.27,130.30,130.16,129.95,12 7.86,125.06,123.25,122.15,121.99,121.50,114.19,111.38,69.58,61.81,58.81,56.30,55.65,31.57,30.23,27.97,22.36,13.76.

[0123] ESI + :529.61.

[0124] Example 4 Synthesis of 2,9,10-trimethoxy-3-((2-nitrobenzyl)oxy)-13-(oct-7-yl-1-yl)-5,6-dihydroisoquinolino[3,2-a]isoquinolino-7-onium (MX4)

[0125] The experimental procedure was the same as in Example 1, except that the first raw material was o-nitrobenzyl bromide and the second raw material was 1-bromooctylene; the NMR results of the final product are as follows:

[0126] 1H NMR(500MHz,DMSO-d6)δ9.94(s,1H),8.08(dd,J=8.6,1.4Hz,1H),7.63(td,J=7.3,1.2Hz,1H),7.60–7.54(m,1H),7 .51(dq,J=7.2,1.1Hz,1H),7.35–7.30(m,2H),7.19(d,J=8.5Hz,1H),7.04(t,J=1.0Hz,1H),5.41(d,J=1.0Hz,2H),4 .63(ddd,J=7.6,4.9,1.2Hz,2H),4.02(s,3H),3.88(d,J=13.9Hz,5H),3.21–3.14(m,2H),2.78(t,J=8.5Hz,2H),2. 12(td,J=5.9,3.0Hz,2H),2.06(t,J=2.9Hz,1H),1.68(tt,J=8.4,7.2Hz,2H),1.52–1.41(m,2H),1.44–1.34(m,4H).

[0127] 13 C NMR(125MHz,DMSO-d6)δ150.63,149.90,149.51,146.88,146.81,143.03, 137.45,135.26,133.19,131.27,130.30,130.16,129.95,127.86,125.06, 123.25,122.15,121.99,121.50,114.19,111.38,83.81,69.58,69.15,61. 81,58.81,56.30,55.65,30.56,28.81,28.59,28.38,28.04,27.97,17.91.

[0128] ESI + :581.69.

[0129] Example 5 Synthesis of 2,9,10-trimethoxy-3-((2-nitrobenzyl)oxy)-13-(pent-4-yn-1-yl)-5,6-dihydroisoquino[3,2-a]isoquinoline-7-onium (MX5)

[0130] The experimental procedure was the same as in Example 1, except that the first raw material was o-nitrobenzyl bromide and the second raw material was 4-bromobutyronitrile; the NMR results of the final product are as follows:

[0131] 1H NMR(500MHz,DMSO-d6)δ9.94(s,1H),8.08(dd,J=8.6,1.4Hz,1H),7.63(td,J=7.3,1.2Hz,1H),7 .60–7.54(m,1H),7.51(dq,J=7.1,1.1Hz,1H),7.35–7.30(m,2H),7.19(d,J=8.5Hz,1H),7.04(t, J=1.0Hz,1H),5.41(d,J=1.0Hz,2H),4.63(ddd,J=7.6,4.9,1.2Hz,2H),4.02(s,3H),3.88(d,J= 13.9Hz,5H),3.21–3.14(m,2H),2.90(t,J=8.5Hz,2H),2.48(t,J=6.0Hz,2H),2.11–1.93(m,2H).

[0132] 13 C NMR(125MHz,DMSO-d6)δ150.63,149.90,149.51,146.88,146.82,143.03,137.11,132.78,132.53,131.27,130.30,130.16,129.95,127 .86,125.06,123.25,122.17,121.99,121.49,119.22,114.19,111.38,69.58,61.81,58.81,56.30,55.65,29.79,27.97,23.88,16.51.

[0133] ESI + :540.60.

[0134] Example 6 Synthesis of 3-(hept-6-en-1-oxy)-2,9,10-trimethoxy-13-(3-methylbut-2-en-1-yl)-5,6-dihydroisoquinolino[3,2-a]isoquinolino-7-onium (MX6)

[0135] The experimental procedure was the same as in Example 1, except that the first raw material was 1-bromoheptene and the second raw material was 3,3-dimethylallyl bromide; the NMR results of the final product are as follows:

[0136] 1H NMR (500MHz, DMSO-d6) δ9.94(s,1H),7.39(d,J=8.5Hz,1H),7.32(s,1H),7.19(d,J=8.8Hz,1H),7.01(t,J=1.0Hz,1H),5.7 7(tt,J=17.1,6.8Hz,1H),5.31(dddd,J=9.1,7.3,3.3,1.6Hz,1H),5.12(ddt,J=17.1,2.1,1.0Hz,1H),4.97(ddt,J=17.1, 2.1,1.1Hz,1H),4.64(ddd,J=7.3,4.6,1.7Hz,2H),4.04–3.97(m,4H),3.89(d,J=11.0Hz,5H),3.46(dp,J=7.4,1.0Hz,2H) ,3.21–3.14(m,2H),2.03(tdt,J=8.0,6.9,1.1Hz,2H),1.73–1.64(m,8H),1.43(qd,J=6.7,5.5Hz,2H),1.39–1.30(m,2H).

[0137] 13 C NMR (125MHz, DMSO-d6) δ150.60,150.29,149.34,147.22,142.90,138.86,136.89,130.31,130.17,129.75,128.59,123.77,122.74,122. 09,121.57,120.78,114.60,114.15,111.29,68.80,61.81,58.10,56 .30,55.65,33.67,29.09,28.68,28.63,27.97,25.86,24.49,19.28.

[0138] ESI + :502.67.

[0139] Example 7 Synthesis of 13-(3,5-dimethoxybenzyl)-3-(hept-6-en-1-yloxy)-2,9,10-trimethoxy-5,6-dihydroisoquinolino[3,2-a]isoquinoline-7-onium (MX7)

[0140] The experimental procedure was the same as in Example 1, except that the first raw material was 1-bromoheptene and the second raw material was 3,5-dimethoxybenzyl bromide; the NMR results of the final product are as follows:

[0141] 1H NMR (500MHz, DMSO-d6) δ9.94(s,1H),7.37(d,J=8.8Hz,1H),7.32(s,1H),7.19(d,J=8.8Hz,1H),7.01(t,J=1.0Hz,1H),6.46(dt,J=2.2, 1.0Hz,2H),6.36(t,J=2.4Hz,1H),5.77(tt,J=17.1,6.8Hz,1H),5.12(ddt,J=17.1,2.2,1.0Hz,1H),4.97(ddt,J=17.1,2.2,1.1Hz,1H) ,4.64(ddd,J=7.3,4.6,1.7Hz,2H),4.08(dt,J=9.5,1.0Hz,1H),4.02(s,3H),4.03–3.97(m,3H),3.89(d,J=11.0Hz,5H),3.79(s,5H),3 .21–3.14(m,2H),2.03(tdt,J=8.0,6.9,1.1Hz,2H),1.69(ddd,J=13.0,7.0,6.1Hz,2H),1.43(qd,J=6.7,5.6Hz,2H),1.39–1.30(m,2H).

[0142] 13 C NMR(125MHz,DMSO-d6)δ160.81,150.60,150.29,149.34,147.26,143.57,139.48,138.86,137.12,131.19,130.60,130.33,123.81,122.77,1 21.08,118.23,114.60,114.15,111.29,108.24,98.82,68.80,61.81, 57.39,56.30,55.65,55.33,36.36,33.67,29.09,28.63,27.97,25.86.

[0143] ESI + :584.73.

[0144] Example 8 Synthesis of 3-(hept-6-en-1-yloxy)-2,9,10-trimethoxy-13-(3-nitrobenzyl)-5,6-dihydroisoquinolino[3,2-a]isoquinoline-7-onium (MX8)

[0145] The experimental procedure was the same as in Example 1, except that the first raw material was 1-bromoheptene and the second raw material was m-nitrobenzyl bromide; the NMR results of the final product are as follows:

[0146] 1 H NMR(500MHz,DMSO-d6)δ9.94(s,1H),8.16(dt,J=8.8,1.6Hz,1H),8.12(tt,J=2.1,1.0Hz,1H),7.59(dd,J=8.8,7.8Hz,1H),7.53–7.47(m,1H),7. 37(d,J=8.8Hz,1H),7.32(s,1H),7.19(d,J=8.8Hz,1H),7.01(t,J=1.0Hz ,1H),5.77(tt,J=17.1,6.8Hz,1H),5.12(ddt,J=17.1,2.1,1.0Hz,1H),4 .97(ddt,J=17.1,2.1,1.1Hz,1H),4.64(ddd,J=7.3,4.6,1.7Hz,2H),4.50(dt,J=9.8,1.0Hz,1H),4.08(dt,J=9.8,1.0Hz,1H),4.04–3.97(m,5H) ,3.89(d,J=11.0Hz,5H),3.21–3.14(m,2H),2.03(tdt,J=8.0,6.9,1.1Hz ,2H),1.73–1.64(m,2H),1.43(qd,J=6.7,5.7Hz,2H),1.39–1.30(m,2H).

[0147] 13 C NMR(125MHz,DMSO-d6)δ150.60,150.29,149.34,148.32,147.26,143.57 ,138.86,138.07,137.12,133.52,131.19,131.09,130.33,129.50,124.1 4,123.81,123.36,122.77,121.08,118.23,114.60,114.15,111.29,68.8 0,61.81,57.39,56.30,55.65,36.55,33.67,29.09,28.63,27.97,25.86.

[0148] ESI + :569.68.

[0149] Example 9 Synthesis of 2,9,10-trimethoxy-13-(3-methylbenzyl)-3-(pent-4-en-1-yloxy)-5,6-dihydroisoquino[3,2-a]isoquinoline-7-onium (MX9)

[0150] The experimental procedure was the same as in Example 1, except that the first raw material was 1-bromopentene and the second raw material was m-methylbenzyl bromide; the NMR results of the final product are as follows:

[0151] 1 H NMR(500MHz,DMSO-d6)δ9.94(s,1H),7.37(d,J=8.8Hz,1H),7.32(s,1H),7.25–7.17(m,2H),7.14(ddq,J=7.4,2.2, 1.0Hz,1H),7.09–7.03(m,1H),7.06–6.99(m,2H),5.74(tt,J=17.1,6.8Hz,1H),5.11(ddt,J=17.1,2.1,1.0Hz,1H), 4.97(ddt,J=17.1,2.1,1.0Hz,1H),4.64(ddd,J=7.3,4.6,1.7Hz,2H),4.22(t,J=1.0Hz,2H),4.09–4.01(m,4H),3.8 9(d,J=11.0Hz,5H),3.21–3.14(m,2H),2.32(s,1H),2.14(tdt,J=8.1,6.9,1.1Hz,2H),1.77(tt,J=8.4,6.8Hz,2H).

[0152] 13 C NMR (125MHz, DMSO-d6) δ150.60,150.37,149.34,147.26,143.57,138.69,137.60,137.44,137.11,131.14,130.73,130.33,129.05,128.80,12 8.67,126.02,123.81,122.77,121.08,118.23,115.13,114.15,111.29 ,69.04,61.81,57.39,56.30,55.65,36.00,30.18,28.68,27.97,21.19.

[0153] ESI + :510.65.

[0154] Example 10 Synthesis of 13-(3-aminopropyl)-2,9,10-trimethoxy-3-(pent-4-en-1-yloxy)-5,6-dihydroisoquino[3,2-a]isoquinoline-7-onium (MX10)

[0155] The experimental procedure was the same as in Example 1, except that the first raw material was 1-bromopentene and the second raw material was 1-bromobutylamine; the NMR results of the final product are as follows:

[0156] 1 H NMR (500MHz, DMSO-d6) δ9.94(s,1H),7.32(d,J=8.0Hz,2H),7.19(d,J=8.5Hz,1H),7.01(t,J=1.1Hz,1H),5.74(tt,J=17.1,6.8Hz,1H),5.11(ddt ,J=17.1,2.1,1.0Hz,1H),4.97(ddt,J=17.1,2.1,1.0Hz,1H),4.63(ddd, J=7.6,4.9,1.2Hz,2H),4.09–4.01(m,4H),3.89(d,J=11.0Hz,5H),3.21–

[0157] 3.14(m,2H),2.87–2.77(m,4H),2.14(tdt,J=8.1,6.9,1.1Hz,2H),1.87(tt,J=8.1,5.3Hz,2H),1.82–1.71(m,4H).

[0158] 13 C NMR (125MHz, DMSO-d6) δ150.63,150.37,149.34,146.82,143.03,137.60,137.11,132.54,132.34,130.22,123.25,122.1 7,121.99,121.49,115.13,114.15,111.29,69.04,61.81,58.81,56.30,55.65,40.83,30.18,29.70,29.09,28.68,27.97.

[0159] ESI + :463.60.

[0160] Example 11 Synthesis of 3-(allyloxy)-13-(3,5-dimethoxybenzyl)-2,9,10-trimethoxy-5,6-dihydroisoquinolino[3,2-a]isoquinoline-7-onium (MX11)

[0161] The experimental procedure was the same as in Example 1, except that the first raw material was 1-bromopropene and the second raw material was 3,5-dimethoxybenzyl bromide; the NMR results of the final product are as follows:

[0162] 1H NMR (500MHz, DMSO-d6) δ9.94(s,1H),7.37(d,J=8.8Hz,1H),7.26(s,1H),7.19(d,J=8.8Hz,1H),7. 00(t,J=1.0Hz,1H),6.46(dt,J=2.2,1.0Hz,2H),6.36(t,J=2.4Hz,1H),6.05(tt,J=16.8,5.6Hz,1H ),5.39(ddt,J=16.8,2.1,1.0Hz,1H),5.31(ddt,J=16.8,2.2,1.0Hz,1H),4.67–4.58(m,4H),4.08 (dt,J=9.5,1.0Hz,1H),4.04–3.97(m,4H),3.88(d,J=13.9Hz,5H),3.79(s,5H),3.21–3.14(m,2H).

[0163] 13 C NMR (125MHz, DMSO-d6) δ160.81,150.60,150.02,149.25,147.26,143.57,139.48,137.12,132.33,131.19,130.60,130.36,123 .81,122.75,121.08,118.50,118.23,113.81,111.34,108.24,98.82,69.59,61.81,57.39,56.30,55.65,55.33,36.36,27.97.

[0164] ESI + :528.62.

[0165] Example 12 Synthesis of 3-(allyloxy)-2,9,10-trimethoxy-13-(oct-7-yl-1-yl)-5,6-dihydroisoquinolino[3,2-a]isoquinolino-7-onium (MX12)

[0166] The experimental procedure was the same as in Example 1, except that the first raw material was 1-bromopropene and the second raw material was 1-bromooctylene; the NMR results of the final product are as follows:

[0167] 1H NMR (500MHz, DMSO-d6) δ9.94(s,1H),7.32(d,J=8.5Hz,1H),7.26(s,1H),7.19(d,J=8.5Hz,1H),6.99(t,J=1. 1Hz,1H),6.05(tt,J=16.8,5.6Hz,1H),5.39(ddt,J=16.8,2.1,1.0Hz,1H),5.31(ddt,J=16.9,2.2,1.0Hz,1H ),4.67–4.58(m,4H),4.02(s,3H),3.88(d,J=13.9Hz,5H),3.21–3.14(m,2H),2.78(t,J=8.5Hz,2H),2.12(td ,J=5.9,3.0Hz,2H),2.06(t,J=2.9Hz,1H),1.68(tt,J=8.4,7.2Hz,2H),1.52–1.41(m,2H),1.44–1.33(m,4H).

[0168] 13 C NMR (125MHz, DMSO-d6) δ150.63,150.02,149.25,146.81,143.03,137.45,135.26,133.19,132.33,130.25,123.25,122.15,121.99, 121.50,118.50,113.80,111.34,83.81,69.59,69.15,61.81,58.81,56.30,55.65,30.56,28.81,28.59,28.38,28.04,27.97,17.91.

[0169] ESI + :486.63.

[0170] Example 13 Synthesis of 13-(hept-6-en-1-yl)-2,9,10-trimethoxy-3-(ethoxy)-5,6-dihydroisoquinolino[3,2-a]isoquinolino-7-onium (MX13)

[0171] The experimental procedure was the same as in Example 1, except that the first raw material was 1-bromoethylene and the second raw material was 1-bromoheptene; the NMR results of the final product are as follows:

[0172] 1H NMR (500MHz, DMSO-d6) δ9.94(s,1H),7.53(s,1H),7.32(d,J=8.5Hz,1H),7.19(d,J=8.5Hz,1H),7.07(t,J=1.0Hz,1H),6.70(s,0H) ,5.77(tt,J=17.1,6.8Hz,1H),5.12(ddt,J=17.1,2.1,1.0Hz,1H),4.97(ddt,J=17.1,2.1,1.1Hz,1H),4.68(dd,J=9.9,2.8Hz,1H) ,4.63(ddd,J=7.6,4.9,1.2Hz,2H),4.27(dd,J=9.9,2.8Hz,1H),4.02(s,3H),3.88(d,J=17.1Hz,5H),3.24(dddd,J=15.9,7.6,4.6 ,1.0Hz,2H),2.78(t,J=8.5Hz,2H),2.03(tdt,J=7.8,6.7,1.1Hz,2H),1.69(tt,J=8.4,6.8Hz,2H),1.39–1.30(m,2H),1.34(s,2H).

[0173] 13 C NMR(125MHz,DMSO-d6)δ150.63,149.09,148.05,147.00,146.81,143.03,139.08,137.46,135.26,133.19,131.35,123.25,12 2.15,122.05,121.99,116.01,114.41,110.64,93.31,61.81,58.81,56.30,56.11,33.79,30.56,28.72,28.49,28.44,27.55.

[0174] ESI + :460.59.

[0175] Example 14 Synthesis of 13-(cyanomethyl)-2,9,10-trimethoxy-3-(ethoxy)-5,6-dihydroisoquino[3,2-a]isoquinoline-7-onium (MX14)

[0176] The experimental procedure was the same as in Example 1, except that the first raw material was 1-bromoethylene and the second raw material was bromoacetonitrile; the NMR results of the final product are as follows:

[0177] 1H NMR (500MHz, DMSO-d6) δ9.86 (s, 1H), 7.53 (s, 1H), 7.39 (d, J = 8.5Hz, 1H), 7.19 ( d,J=8.8Hz,1H),7.07(t,J=1.0Hz,1H),6.70(s,0H),4.68(dd,J=9.9,2.8Hz,1H ),4.63(ddd,J=7.3,4.6,1.1Hz,2H),4.27(dd,J=9.9,2.8Hz,1H),4.20(s,2H), 4.02(s,3H),3.88(d,J=17.1Hz,5H),3.24(dddd,J=15.9,7.6,4.6,1.0Hz,2H).

[0178] 13 C NMR(125MHz,DMSO-d6)δ150.60,149.09,148.05,147.41,147.00,142.69,136.10,131.39,128.89,127.79, 123.47,122.02,121.43,120.80,117.11,116.01,110.73,93.31,61.81,58.16,56.30,56.11,27.55,18.88.

[0179] ESI + :403.46.

[0180] Example 15 Synthesis of 2,9,10-trimethoxy-13-(3-nitrobenzyl)-3-(oct-7-yn-1-oxy)-5,6-dihydroisoquinoline[3,2-a]isoquinoline-7-onium (MX15)

[0181] The experimental procedure was the same as in Example 1, except that the first raw material was 1-bromooctyne and the second raw material was m-nitrobenzyl bromide; the NMR results of the final product are as follows:

[0182] 1H NMR(500MHz,DMSO-d6)δ9.94(s,1H),8.16(dt,J=8.8,1.6Hz,1H),8.12(tt,J=2.0,1.0Hz,1H),7.59(dd,J=8.8,7.8Hz, 1H),7.53–7.47(m,1H),7.37(d,J=8.8Hz,1H),7.32(s,1H),7.19(d,J=8.8Hz,1H),7.01(t,J=1.0Hz,1H),4.64(ddd,J=7 .3,4.6,1.7Hz,2H),4.50(dt,J=9.8,1.0Hz,1H),4.08(dt,J=9.8,1.0Hz,1H),4.04–3.97(m,4H),3.89(d,J=11.0Hz,5H) ,3.21–3.14(m,2H),2.12(td,J=6.0,3.0Hz,2H),2.06(t,J=2.9Hz,1H),1.77(tt,J=7.4,6.0Hz,2H),1.55–1.34(m,6H).

[0183] 13 C NMR(125MHz,DMSO-d6)δ150.60,150.29,149.34,148.32,147.26,143.57, 138.07,137.12,133.52,131.19,131.09,130.33,129.50,124.14,123.81, 123.36,122.77,121.08,118.23,114.15,111.29,83.81,69.15,68.80,61. 81,57.39,56.30,55.65,36.55,29.35,28.28,28.06,27.97,26.05,17.91.

[0184] ESI + :581.69.

[0185] Example 16 Synthesis of 13-(3-cyanopropyl)-3-(hex-5-yn-1-yloxy)-2,9,10-trimethoxy-5,6-dihydroisoquinolino[3,2-a]isoquinoline-7-onium (MX16)

[0186] The experimental procedure was the same as in Example 1, except that the first raw material was 1-bromohexyne and the second raw material was 1-bromobutyronitrile; the NMR results of the final product are as follows:

[0187] 1H NMR (500MHz, DMSO-d6) δ9.94 (s, 0H), 7.32 (d, J = 8.0Hz, 1H), 7.01 (t, J = 1.1Hz, 0H), 4.63 (dd d,J=7.6,4.9,1.2Hz,1H),4.08(t,J=5.0Hz,1H),4.02(s,1H),3.89(d,J=11.0Hz,2H),3.21–

[0188] 3.14(m,1H),2.90(t,J=8.5Hz,1H),2.51–2.44(m,2H),2.11–1.93(m,2H),1.81(tt,J=7.5,5.0Hz,1H),1.58(tt,J=7.5,5.9Hz,1H).

[0189] 13 C NMR (125MHz, DMSO-d6) δ150.63,150.37,149.34,146.82,143.03,137.11,132.78,132.53,130.22,123.25,122.17,121.99,121. 49,119.22,114.15,111.29,83.76,69.16,69.15,61.81,58.81,56.30,55.65,29.79,28.67,27.97,25.28,23.88,18.09,16.51.

[0190] ESI + :485.60.

[0191] Example 17 Synthesis of 13-(4-bromobenzyl)-3-(4-cyanobutoxy)-2,9,10-trimethoxy-5,6-dihydroisoquinolino[3,2-a]isoquinoline-7-onium (MX17)

[0192] The experimental procedure was the same as in Example 1, except that the first raw material was 1-bromopentanonitrile and the second raw material was p-bromobenzyl bromide; the NMR results of the final product are as follows:

[0193] 1H NMR(500MHz,DMSO-d6)δ9.94(s,1H),7.51–7.45(m,2H),7.37(d,J=8.8Hz,1H) ,7.32(s,1H),7.24–7.16(m,3H),7.01(t,J=1.0Hz,1H),4.64(ddd,J=7.3,4.6 ,1.7Hz,2H),4.18(t,J=1.1Hz,2H),4.08(t,J=5.0Hz,2H),4.02(s,3H),3.89( d,J=11.0Hz,5H),3.21–3.14(m,2H),2.41(t,J=5.8Hz,2H),1.82–1.70(m,4H).

[0194] 13 C NMR (125MHz, DMSO-d6) δ150.60,150.37,149.34,147.26,143.57,137.87,137.11,131.62,131.14,131.03,130.33,129.75,123.81 ,122.77,121.08,120.49,119.41,118.23,114.15,111.29,69.22,61.81,57.39,56.30,55.65,35.88,28.57,27.97,22.12,16.76.

[0195] ESI + :588.52.

[0196] Example 18 Synthesis of 2,9,10-trimethoxy-13-(4-methylbenzyl)-3-((4-methylbenzyl)oxy)-5,6-dihydroisoquinolino[3,2-a]isoquinolino-7-onium (MX18)

[0197] The experimental procedure was the same as in Example 1, except that both the first and second raw materials were p-methylbenzyl bromide; the NMR results of the final product are as follows:

[0198] 1H NMR(500MHz,DMSO-d6)δ9.94(s,1H),7.37(d,J=8.8Hz,1H),7.34–7.27(m,3H),7.19(d ,J=8.8Hz,1H),7.17(s,1H),7.14(dq,J=7.8,1.2Hz,3H),7.11–7.06(m,2H),7.04(t,J =1.1Hz,1H),5.12(t,J=1.0Hz,2H),4.64(ddd,J=7.3,4.6,1.7Hz,2H),4.19(t,J=1.0H z,2H),4.02(s,2H),3.88(d,J=13.9Hz,5H),3.21–3.14(m,2H),2.34(q,J=0.9Hz,6H).

[0199] 13 C NMR(125MHz,DMSO-d6)δ150.60,149.84,149.48,147.26,143.57,138.34,138.17,137.11,136.95,134.01,131.14,131.00,130.41,129 .27,129.09,128.18,128.03,123.81,122.77,121.08,118.23,114.29,111.38,71.29,61.81,57.39,56.30,55.65,36.00,27.97,21.05.

[0200] ESI + 546.69.

[0201] Example 19 Synthesis of 13-benzyl-3-(3-cyanopropoxy)-2,9,10-trimethoxy-5,6-dihydroisoquinolino[3,2-a]isoquinoline-7-onium (MX19)

[0202] The experimental procedure was the same as in Example 1, except that the first raw material was 1-bromobutyronitrile and the second raw material was benzyl bromo; the NMR results of the final product are as follows:

[0203] 1H NMR(500MHz,DMSO-d6)δ9.94(s,1H),7.37(d,J=8.8Hz,1H),7.32(s,1H),7.28(dd,J=7 .9,6.8Hz,2H),7.25–7.20(m,2H),7.23–7.16(m,2H),7.01(t,J=1.0Hz,1H),4.64(ddd ,J=7.3,4.6,1.7Hz,2H),4.16(t,J=1.0Hz,2H),4.12(t,J=6.2Hz,2H),4.02(s,3H),3. 89(d,J=11.0Hz,5H),3.21–3.14(m,2H),2.58(t,J=6.3Hz,2H),2.13(p,J=6.2Hz,2H).

[0204] 13 C NMR (125MHz, DMSO-d6) δ150.60,150.45,149.39,147.26,143.57,138.16,137.12,131.14,130.99,130.33,127.98,127.82,127 .18,123.81,122.77,121.08,119.17,118.23,114.15,111.29,68.60,61.81,57.39,56.30,55.65,36.11,27.97,25.74,14.07.

[0205] ESI + :495.6.

[0206] Example 20 Synthesis of 2,9,10-trimethoxy-13-(3-methylbut-2-en-1-yl)-3-(prop-2-yn-1-yloxy)-5,6-dihydroisoquinolino[3,2-a]isoquinoline-7-onium (MX20)

[0207] The experimental procedure was the same as in Example 1, except that the first raw material was bromoacetonitrile and the second raw material was 3,3-dimethylallyl bromide; the NMR results of the final product are as follows:

[0208] 1H NMR(500MHz,DMSO-d6)δ9.94(s,1H),7.39(d,J=8.5Hz,1H),7.32(s,1H),7.19(d,J=8.8Hz ,1H),7.07(t,J=1.1Hz,1H),5.31(dddd,J=9.1,7.3,3.3,1.6Hz,1H),4.82(d,J=2.9Hz,2H ),4.64(ddd,J=7.3,4.6,1.7Hz,2H),4.02(s,3H),3.88(d,J=15.9Hz,5H),3.46(dp,J=7.4 ,1.1Hz,2H),3.36(s,0H),3.36(d,J=6.1Hz,0H),3.21–3.14(m,2H),1.68(q,J=1.2Hz,6H).

[0209] 13 C NMR (125MHz, DMSO-d6) δ150.60,149.16,149.12,147.22,142.90,136.89,130.45,130.17,129.75,128.59,123.77,122.7 6,122.09,121.57,120.78,114.55,111.30,78.41,76.70,61.81,58.28,58.15,56.30,55.66,28.68,27.97,24.49,19.28.

[0210] ESI + :444.55.

[0211] Example 21 Synthesis of 3-(cyanomethoxy)-13-(hex-5-yn-1-yl)-2,9,10-trimethoxy-5,6-dihydroisoquinolino[3,2-a]isoquinolino-7-onium (MX21)

[0212] The experimental procedure was the same as in Example 1, except that the first raw material was bromoacetonitrile and the second raw material was 6-bromo-1-hexyne; the NMR results of the final product are as follows:

[0213] 1H NMR (500MHz, DMSO-d6) δ9.94 (s, 1H), 7.35–7.30 (m, 2H), 7.19 (d, J = 8.5Hz, 1H), 7.06 (t, J = 1. 1Hz,1H),4.98(s,2H),4.63(ddd,J=7.6,4.9,1.2Hz,2H),4.02(s,3H),3.88(d,J=15.9Hz,5H ),3.21–3.14(m,2H),2.83(dt,J=15.8,7.3Hz,1H),2.74(dt,J=15.6,7.3Hz,1H),2.46(td,J =5.7, 3.0Hz, 2H), 2.06 (t, J = 3.1Hz, 1H), 1.79 (tt, J = 7.4, 6.1Hz, 2H), 1.59 (p, J = 5.9Hz, 2H).

[0214] 13 C NMR (125MHz, DMSO-d6) δ150.63,149.15,148.42,146.82,143.03,137.46,134.63,133.19,130.35,123.25,122.15,121.9 9,121.49,116.24,114.54,111.38,83.79,69.15,61.81,58.81,56.30,55.66,54.47,30.56,27.97,27.61,27.50,18.24.

[0215] ESI + :457.55.

[0216] Example 22 Synthesis of 13-(3,5-dimethoxybenzyl)-3-((4-fluorobenzyl)oxy)-2,9,10-trimethoxy-5,6-dihydroisoquinolino[3,2-a]isoquinoline-7-onium (MX22)

[0217] The experimental procedure was the same as in Example 1, except that the first raw material was p-fluorobenzyl bromide and the second raw material was 3,5-dimethoxybenzyl bromide; the NMR results of the final product are as follows:

[0218] 1H NMR (500MHz, DMSO-d6) δ9.94 (s, 1H), 7.51 (ddt, J=8.1, 5.1, 1.0Hz, 2H), 7.37 (d, J=8.8Hz, 1H),7.32(s,1H),7.21–7.14(m,3H),7.04(t,J=1.1Hz,1H),6.46(dt,J=2.2,1.0Hz,2H),6. 36(t,J=2.4Hz,1H),5.12(t,J=1.0Hz,2H),4.64(ddd,J=7.3,4.6,1.7Hz,2H),4.08(dt,J=9 .5,1.0Hz,1H),4.04–3.97(m,3H),3.88(d,J=13.9Hz,5H),3.79(s,5H),3.21–3.14(m,2H).

[0219] 13 C NMR(125MHz,DMSO-d6)δ163.44,161.42,160.81,150.60,149.84,149.48,14 7.26,143.57,139.48,137.12,132.91,132.89,131.19,130.60,130.41,129 .54,129.47,123.81,122.75,121.08,118.23,115.26,115.10,114.29,111.38,108.24,98.82,71.35,61.81,57.39,56.30,55.65,55.33,36.36,27.97.

[0220] ESI + :596.67.

[0221] Example 23 Synthesis of 3-((4-fluorobenzyl)oxy)-13-(hept-6-en-1-yl)-2,9,10-trimethoxy-5,6-dihydroisoquinolino[3,2-a]isoquinolino-7-onium (MX23)

[0222] The experimental procedure was the same as in Example 1, except that the first raw material was p-fluorobenzyl bromide and the second raw material was 7-bromo-1-heptene; the NMR results of the final product are as follows:

[0223] 1H NMR(500MHz,DMSO-d6)δ9.94(s,1H),7.51(ddt,J=8.1,5.1,1.0Hz,2H),7.35–7.30(m,2H),7.21–7.14( m,3H),7.04(t,J=1.0Hz,1H),5.77(tt,J=17.1,6.8Hz,1H),5.16–5.08(m,3H),4.97(ddt,J=17.1,2.1,1 .1Hz,1H),4.63(ddd,J=7.6,4.9,1.2Hz,2H),4.02(s,3H),3.88(d,J=13.9Hz,5H),3.21–3.14(m,2H),2 .78(t,J=8.5Hz,2H),2.03(tdt,J=7.8,6.7,1.1Hz,2H),1.69(tt,J=8.5,6.8Hz,2H),1.39–1.30(m,4H).

[0224] 13 C NMR(125MHz,DMSO-d6)δ163.44,161.42,150.63,149.84,149.48,146.81,143 .03,139.08,137.45,135.26,133.19,132.91,132.89,130.30,129.54,129.4 7,123.25,122.15,121.99,121.50,115.26,115.10,114.41,114.25,111.38,71.35,61.81,58.81,56.30,55.65,33.79,30.56,28.72,28.49,28.44,27.97.

[0225] ESI + :542.67.

[0226] Example 24 Synthesis of 13-allyl-3-((4-chlorobenzyl)oxy)-2,9,10-trimethoxy-5,6-dihydroisoquinolino[3,2-a]isoquinoline-7-onium (MX24)

[0227] The experimental procedure was the same as in Example 1, except that the first raw material was p-chlorobenzyl bromide and the second raw material was 3-bromopropene; the NMR results of the final product are as follows:

[0228] 1H NMR (500MHz, DMSO-d6) δ9.94 (s, 1H), 7.47 (dt, J = 8.2, 1.0 Hz, 2H), 7.47–7.39 (m, 2H), 7.39 (d, J = 8. 5Hz,1H),7.32(s,1H),7.19(d,J=8.8Hz,1H),7.04(t,J=1.0Hz,1H),5.89(tt,J=16.4,8.1Hz,1H), 5.21–5.13(m,1H),5.12(t,J=1.0Hz,2H),5.07(ddt,J=16.4,2.1,1.0Hz,1H),4.64(ddd,J=7.3,4. 6,1.7Hz,2H),4.02(s,3H),3.88(d,J=13.9Hz,5H),3.40(dt,J=8.0,1.0Hz,2H),3.21–3.14(m,2H).

[0229] 13 C NMR(125MHz,DMSO-d6)δ150.60,149.84,149.48,147.22,142.94,137.27,136.50,135.07,133.86,130.32,130.31,129.30, 128.67,128.55,122.78,122.09,121.63,120.78,116.29,114.25,111.38,71.31,61.81,58.10,56.30,55.65,34.24,27.97.

[0230] ESI + :503.01.

[0231] Example 25 Synthesis of 3-((4-chlorobenzyl)oxy)-2,9,10-trimethoxy-13-(prop-2-yn-1-yl)-5,6-dihydroisoquinolino[3,2-a]isoquinolino-7-onium (MX25)

[0232] The experimental procedure was the same as in Example 1, except that the first raw material was p-chlorobenzyl bromide and the second raw material was 3-bromopropyne; the NMR results of the final product are as follows:

[0233] 1H NMR(500MHz,DMSO-d6)δ9.86(s,1H),7.47(dt,J=8.2,1.0Hz,2H),7.47–7.39(m,2 H),7.39(d,J=8.5Hz,1H),7.32(s,1H),7.19(d,J=8.8Hz,1H),7.04(t,J=1.0Hz,1 H),5.12(t,J=1.0Hz,2H),4.74(d,J=2.9Hz,2H),4.63(ddd,J=7.3,4.6,1.1Hz,2H ),4.02(s,3H),3.88(d,J=13.9Hz,5H),3.21–3.14(m,2H),2.69(t,J=2.9Hz,1H).

[0234] 13 C NMR(125MHz,DMSO-d6)δ150.60,149.84,149.48,147.29,142.49,136.75,135.07,133.86,130.36,130.18,129.40,129.30 ,128.55,122.70,122.00,121.29,120.79,114.25,111.42,83.55,72.39,71.31,61.81,58.16,56.30,55.65,27.97,21.95.

[0235] ESI + :501.00.

[0236] Example 26 Synthesis of 2,9,10-trimethoxy-13-(3-methylbut-2-en-1-yl)-3-((3-methylbut-2-en-1-yloxy)-5,6-dihydroisoquinolino[3,2-a]isoquinoline-7-onthium (MX26)

[0237] The experimental procedure was the same as in Example 1, with both the first and second raw materials being 3,3-dimethylallyl bromide; the NMR results of the final product are as follows:

[0238] 1H NMR(500MHz,DMSO-d6)δ9.94(s,1H),7.39(d,J=8.5Hz,1H),7.26(s,1H),7.19(d,J=8.8Hz, 1H),7.00(t,J=1.0Hz,1H),5.31(ddt,J=7.3,5.7,1.6Hz,1H),5.28(ddt,J=6.5,3.2,1.6Hz, 1H),4.67–4.60(m,3H),4.61(dq,J=2.1,1.0Hz,1H),4.02(s,3H),3.88(d,J=13.9Hz,5H),3 .46(dp,J=7.3,1.0Hz,2H),3.21–3.14(m,2H),1.75(q,J=1.1Hz,6H),1.68(q,J=1.1Hz,6H).

[0239] 13 C NMR (125MHz, DMSO-d6) δ150.60,150.34,149.32,147.22,142.90,137.69,136.89,130.37,130.17,129.75,128.59,123.77,122.7 6,122.09,121.57,120.78,119.22,113.81,111.34,66.09,61.81,58.10,56.30,55.65,28.68,27.97,24.63,24.49,19.90,19.28.

[0240] ESI + :474.62.

[0241] Example 27 Synthesis of 13-heptyl-3-(hex-5-yn-1-yloxy)-2,9,10-trimethoxy-5,6-dihydroisoquinolino[3,2-a]isoquinoline-7-onium (MX27)

[0242] The experimental procedure was the same as in Example 1, except that the first raw material was 6-bromo-1-hexyne and the second raw material was 1-bromo-n-nonane; the NMR results of the final product are as follows:

[0243] 1H NMR (500MHz, DMSO-d6) δ9.94 (s, 0H), 7.32 (d, J = 8.0Hz, 1H), 7.01 (t, J = 1.1Hz, 0H), 4.63 (ddd, J = 7 .6,4.9,1.2Hz,1H),4.08(t,J=5.0Hz,1H),4.02(s,1H),3.89(d,J=11.0Hz,2H),3.21–3.14(m,1H) ,2.78(t,J=8.5Hz,1H),2.47(td,J=5.9,3.0Hz,1H),1.81(tt,J=7.5,5.0Hz,1H),1.69(tt,J=8.5, 7.2Hz,1H),1.58(tt,J=7.5,5.9Hz,1H),1.39–1.31(m,1H),1.34–1.22(m,5H),0.92–0.86(m,1H).

[0244] 13 C NMR(125MHz,DMSO-d6)δ150.63,150.37,149.34,146.81,143.03,137.45 ,135.26,133.19,130.22,123.25,122.15,121.99,121.50,114.15,111. 29,83.76,69.16,69.15,61.81,58.81,56.30,55.65,31.74,30.56,29.6 6,29.34,29.22,29.21,28.81,28.67,27.97,25.28,22.67,18.09,14.06.

[0245] ESI + 544.76.

[0246] Example 28 Synthesis of 2,9,10-trimethoxy-13-(pent-4-en-1-yl)-3-(pent-4-yn-1-yloxy)-5,6-dihydroisoquinolino[3,2-a]isoquinolino-7-onium (MX28)

[0247] The experimental procedure was the same as in Example 1, except that the first raw material was 5-bromo-1-pentyne and the second raw material was 5-bromo-1-pentyne; the NMR results of the final product are as follows:

[0248] 1H NMR(500MHz,)δ7.32(d,J=8.0Hz,1H),7.01(t,J=1.1Hz,0H),4.63(ddd,J=7. 6,4.9,1.2Hz,1H),4.14(t,J=6.1Hz,1H),4.02(s,1H),3.89(d,J=11.0Hz,2H ),3.21–3.14(m,1H),2.89(t,J=8.5Hz,1H),2.57(td,J=6.1,3.0Hz,2H),2.0 7(dt,J=6.0,3.0Hz,1H),1.95(p,J=6.2Hz,1H),1.86(tt,J=8.4,6.0Hz,1H).

[0249] 13 C NMR(125MHz,)δ150.63,150.45,149.39,146.82,143.03,137.11,132.73,132.57,130.22,123.25,122.17,121.99,121.49, 114.15,111.29,83.89,83.65,69.25,69.15,68.63,61.81,58.81,56.30,55.65,29.84,28.27,27.97,26.69,17.90,15.64.

[0250] ESI + :470.59.

[0251] Example 29 Synthesis of 3-(allyloxy)-2,9,10-trimethoxy-13-(3-methylbut-2-en-1-yl)-5,6-dihydroisoquinolino[3,2-a]isoquinolino-7-onium (MX29)

[0252] The experimental procedure was the same as in Example 1, except that the first raw material was 3-bromopropene and the second raw material was 3,3-dimethylallyl bromide; the NMR results of the final product are as follows:

[0253] 1H NMR(500MHz,DMSO-d6)δ9.94(s,1H),7.39(d,J=8.5Hz,1H),7.26(s,1H),7.19(d,J =8.8Hz,1H),7.00(t,J=1.1Hz,1H),6.05(tt,J=16.8,5.6Hz,1H),5.39(ddt,J=16. 8,2.1,1.0Hz,1H),5.35–5.27(m,2H),4.67–4.58(m,4H),4.02(s,3H),3.88(d,J=1 3.9Hz, 5H), 3.46 (dp, J=7.3, 1.0Hz, 2H), 3.21–3.14 (m, 2H), 1.68 (q, J=1.2Hz, 6H).

[0254] 13 C NMR(125MHz,DMSO-d6)δ150.60,150.02,149.25,147.22,142.90,136.89,132.33,130.37,130.17,129.75,128.59,123.77 ,122.76,122.09,121.57,120.78,118.50,113.81,111.34,69.59,61.81,58.10,56.30,55.65,28.68,27.97,24.49,19.28.

[0255] ESI + :446.57.

[0256] Example 30 Synthesis of (E)-3-(but-2-en-1-yloxy)-2,9,10-trimethoxy-13-(3-methylbut-2-en-1-yl)-5,6-dihydroisoquinolino[3,2-a]isoquinoline-7-onium (MX30)

[0257] The experimental procedure was the same as in Example 1, except that the first raw material was crotonyl bromide and the second raw material was 3,3-dimethylallyl bromide; the NMR results of the final product are as follows:

[0258] 1H NMR (500MHz, DMSO-d6) δ9.94 (s, 1H), 7.39 (d, J = 8.5Hz, 1H), 7.26 (s, 1H), 7.19 ( d,J=8.8Hz,1H),7.00(t,J=1.1Hz,1H),5.73–5.58(m,2H),5.31(dddd,J=9.1,7. 3,3.3,1.6Hz,1H),4.68–4.61(m,4H),4.02(s,3H),3.88(d,J=13.9Hz,5H),3.4 6(dp,J=7.3,1.0Hz,2H),3.21–3.14(m,2H),1.67(ddt,J=6.1,1.9,1.2Hz,10H).

[0259] 13 C NMR (125MHz, DMSO-d6) δ150.60,150.47,149.25,147.22,142.90,136.89,130.37,130.17,129.75,128.85,128.59,127.26,12 3.77,122.76,122.09,121.57,120.78,113.81,111.34,69.18,61.81,58.10,56.30,55.65,28.68,27.97,24.49,19.28,17.70.

[0260] ESI + :460.59.

[0261] Example 31 Synthesis of 2,9,10-trimethoxy-13-(2-methylbenzyl)-3-((3-methylbut-2-en-1-yl)oxy)-5,6-dihydroisoquinolino[3,2-a]isoquinolino-7-onium (MX31)

[0262] The experimental procedure was the same as in Example 1, except that the first raw material was 3,3-dimethylallyl bromide and the second raw material was o-methylbenzyl bromide; the NMR results of the final product are as follows:

[0263] 1H NMR(500MHz,DMSO-d6)δ9.94(s,1H),7.37(d,J=8.8Hz,1H),7.26(s,1H),7.19(d,J =8.8Hz,1H),7.17–7.08(m,4H),7.00(t,J=1.1Hz,1H),5.28(ddp,J=6.5,3.1,1.6Hz ,1H),4.67–4.59(m,4H),4.10(dd,J=11.3,0.9Hz,1H),4.07–4.01(m,1H),4.02(s, 3H),3.88(d,J=13.9Hz,5H),3.21–3.14(m,2H),2.32(s,3H),1.75(q,J=1.1Hz,6H).

[0264] 13 C NMR(125MHz,DMSO-d6)δ150.60,150.34,149.32,147.26,143.57,138.68,137.69,137.50,136.68,131.17,130.63,130.36,129.83,128.61,12 6.89,126.75,123.81,122.77,120.92,119.22,118.23,113.81,111.34 ,66.09,61.81,57.39,56.30,55.65,33.68,27.97,24.62,19.90,19.57.

[0265] ESI + :510.65.

[0266] Example 32 Synthesis of 2,9,10-trimethoxy-13-(2-methylbenzyl)-3-((3-methylbut-2-en-1-yl)oxy)-5,6-dihydroisoquinolino[3,2-a]isoquinolino-7-onium (MX32)

[0267] The experimental procedure was the same as in Example 1, except that the first raw material was 3,5-dimethylbenzyl bromide and the second raw material was 3,3-dimethylallyl bromide; the NMR results of the final product are as follows:

[0268] 1H NMR(500MHz,DMSO-d6)δ9.94(s,0H),7.39(d,J=8.5Hz,1H),7.19(d,J=8.8Hz,0H),7. 06–6.98(m,2H),6.80(t,J=2.2Hz,0H),5.31(dddd,J=9.1,7.3,3.3,1.6Hz,1H),5.08( t,J=1.1Hz,1H),4.64(ddd,J=7.3,4.6,1.7Hz,1H),4.02(s,1H),3.88(d,J=13.9Hz,3H ),3.46(dp,J=7.3,1.0Hz,1H),3.21–3.14(m,1H),2.25(s,3H),1.68(q,J=1.2Hz,3H).

[0269] 13 C NMR (125MHz, DMSO-d6) δ150.60,149.84,149.48,147.22,142.90,137.61,136.89,136.25,130.41,130.17,129.82,129.75,128.59,12 7.53,123.77,122.76,122.09,121.57,120.78,114.29,111.38,71.62,61.81,58.10,56.30,55.65,28.68,27.97,24.49,21.08,19.28.

[0270] ESI + 524.68.

[0271] Example 33 Synthesis of 13-(3,5-dimethoxybenzyl)-3-((3,5-dimethylbenzyl)oxy)-2,9,10-trimethoxy-5,6-dihydroisoquinoline[3,2-a]isoquinoline-7-onium (MX33)

[0272] The experimental procedure was the same as in Example 1, except that the first raw material was 3,5-dimethylbenzyl bromide and the second raw material was 3,5-dimethoxybenzyl bromide; the NMR results of the final product are as follows:

[0273] 1H NMR(500MHz,DMSO-d6)δ9.94(s,0H),7.37(d,J=8.8Hz,0H),7.19(d,J=8.8Hz,0H),7.06 –6.98(m,2H),6.80(t,J=2.2Hz,0H),6.46(dt,J=2.1,1.0Hz,1H),6.36(t,J=2.4Hz,1H) ,5.08(t,J=1.1Hz,1H), 4.64(ddd,J=7.3,4.6,1.7Hz,1H), 4.08(dt,J=9.5,1.0Hz,1H), 4.04–3.97(m,2H),3.88(d,J=13.9Hz,3H),3.79(s,3H),3.21–3.14(m,1H),2.25(s,3H).

[0274] 13 C NMR (125MHz, DMSO-d6) δ160.81,150.60,149.84,149.48,147.26,143.57,139.48,137.61,137.12,136.25,131.19,130.60,130.41,129.82 ,127.53,123.81,122.75,121.08,118.23,114.29,111.38,108.24,9 8.82,71.62,61.81,57.39,56.30,55.65,55.33,36.36,27.97,21.08.

[0275] ESI + :606.74.

[0276] Example 34 Synthesis of 14-(3-aminopropyl)-3-((3,5-dimethoxybenzyl)oxy)-2,9,10-trimethoxy-5,6-dihydroisoquinoline[3,2-a]isoquinoline-7-onium (MX34)

[0277] The experimental procedure was the same as in Example 1, except that the first raw material was 3,5-dimethoxybenzyl bromide and the second raw material was 4-bromobutylamine; the NMR results of the final product are as follows:

[0278] 1H NMR(500MHz,DMSO-d6)δ9.94(s,0H),7.35–7.30(m,1H),7.19(d,J=8.5Hz,0H),7.04(t, J=1.0Hz,0H),6.63(dt,J=2.3,1.2Hz,1H),6.39(t,J=2.4Hz,0H),5.12(t,J=1.0Hz,1H) ,4.63(ddd,J=7.6,4.9,1.2Hz,1H),4.02(s,1H),3.88(d,J=13.9Hz,3H),3.79(s,3H),3 .21–3.14(m,1H),2.87–2.77(m,2H),1.87(tt,J=8.1,5.3Hz,1H),1.74(t,J=6.3Hz,1H).

[0279] 13 C NMR (125MHz, DMSO-d6) δ160.51,150.63,149.93,149.48,146.82,143.03,138.24,137.11,132.54,132.34,130.30,123.25,12 2.17,121.99,121.49,114.25,111.38,107.23,99.53,71.46,61.81,58.81,56.30,55.65,55.33,40.83,29.70,29.09,27.97.

[0280] ESI + :545.66.

[0281] Example 35 Synthesis of 4-(4-aminobutoxy)-13-(aminomethyl)-2,9,10-trimethoxy-5,6-dihydroisoquinoline[3,2-a]isoquinoline-7-onium (MX35)

[0282] The experimental procedure was the same as in Example 1, except that the first raw material was 4-bromobutylamine and the second raw material was bromoethylamine; the NMR results of the final product are as follows:

[0283] 1H NMR(500MHz,DMSO-d6)δ9.96(s,1H),7.38(d,J=8.8Hz,1H),7.32(s,1H),7.19(d,J=8.8 Hz,1H),7.01(t,J=1.1Hz,1H),5.86(q,J=6.8Hz,1H),5.51(q,J=6.8Hz,1H),4.63(ddd, J=7.3,4.6,1.1Hz,2H),4.01–3.91(m,4H),3.89(d,J=11.0Hz,5H),3.21–3.14(m,2H),2 .79(tt,J=6.4,5.1Hz,2H),2.01(t,J=6.5Hz,2H),1.80–1.71(m,2H),1.64–1.55(m,2H).

[0284] 13 C NMR(125MHz,DMSO-d6)δ150.60,150.37,149.39,146.96,142.67,135.53,130.71,130.24,126.98,122.33,12 1.73,121.05,120.49,114.15,111.33,69.09,61.81,58.16,56.30,55.65,43.00,40.94,28.90,27.97,27.48.

[0285] ESI + :438.55.

[0286] Example 36 Synthesis of 13-allyl-2,9,10-trimethoxy-3-(nonoxy)-5,6-dihydroisoquinolino[3,2-a]isoquinoline-7-onium (MX36)

[0287] The experimental procedure was the same as in Example 1, except that the first raw material was 1-bromononane and the second raw material was 3-bromopropene; the NMR results of the final product are as follows:

[0288] 1H NMR (500MHz, DMSO-d6) δ9.94(s,1H),7.39(d,J=8.5Hz,1H),7.32(s,1H),7.19(d,J=8.8Hz,1H),7.01(t,J=1.1 Hz,1H),5.89(tt,J=16.5,8.1Hz,1H),5.17(ddt,J=16.4,2.1,1.0Hz,1H),5.07(ddt,J=16.3,2.1,1.0Hz,1H),4 .64(ddd,J=7.3,4.6,1.7Hz,2H),4.04–3.97(m,5H),3.89(d,J=11.0Hz,5H),3.40(dt,J=8.0,1.0Hz,2H),3.21 –3.14(m,2H),1.77(tt,J=7.4,6.0Hz,2H),1.44(dq,J=8.0,6.9Hz,2H),1.36–1.22(m,10H),0.94–0.85(m,3H).

[0289] 13 C NMR (125MHz, DMSO-d6) δ150.60,150.29,149.34,147.22,142.94,137.27,136.50,130.31,130.21,128.67,122.78,122.09,121.63,120 .78,116.29,114.15,111.29,68.80,61.81,58.10,56.30,55.65,34.24,31.74,29.41,29.24,29.11,29.09,27.97,26.21,22.67,14.06.

[0290] ESI + :504.69.

[0291] Example 37 Synthesis of 2,9,10-trimethoxy-3-(nonoxy)-13-octyl-5,6-dihydroisoquinoline[3,2-a]isoquinoline-7-onium (MX37)

[0292] The experimental procedure was the same as in Example 1, except that the first raw material was 1-bromooctane and the second raw material was 1-bromooctane; the NMR results of the final product are as follows:

[0293] 1H NMR(500MHz,DMSO-d6)δ9.94(s,0H),7.32(d,J=8.0Hz,1H),7.01(t,J=1.1Hz,0H) ,4.63(ddd,J=7.6,4.9,1.2Hz,1H),4.04–3.97(m,2H),3.89(d,J=11.0Hz,2H),3. 21–3.14(m,1H),2.78(t,J=8.5Hz,1H),1.77(tt,J=7.4,6.0Hz,1H),1.69(tt,J=8 .5,7.2Hz,1H),1.43(dq,J=7.8,6.9Hz,1H),1.39–1.23(m,9H),0.94–0.85(m,3H).

[0294] 13 C NMR(125MHz,DMSO-d6)δ150.63,150.29,149.34,146.81,143.03,137.45,135.26,133.19,130.22,123.25,122.15,121.99,121.50,114.15,1 11.29,68.80,61.81,58.81,56.30,55.65,31.76,31.69,30.56,29.41, 29.32,29.29,29.25,29.22,29.21,28.81,27.97,26.10,22.68,14.06.

[0295] ESI + :576.84.

[0296] Example 38 Synthesis of 3-butoxy-13-(3,5-dimethoxybenzyl)-2,9,10-trimethoxy-5,6-dihydroisoquinoline[3,2-a]isoquinoline-7-onium (MX38)

[0297] The experimental procedure was the same as in Example 1, except that the first raw material was 1-bromobutane and the second raw material was 3,5-dimethoxybenzyl bromide; the NMR results of the final product are as follows:

[0298] 1H NMR(500MHz,DMSO-d6)δ9.94(s,0H),7.37(d,J=8.8Hz,0H),7.19(d,J=8.8Hz,0H),7.0 1(t,J=1.0Hz,1H),6.46(dt,J=2.2,1.0Hz,1H),6.36(t,J=2.4Hz,1H),4.64(ddd,J=7.3 ,4.6,1.7Hz,1H),4.11–3.97(m,2H),4.02(s,2H),3.89(d,J=11.0Hz,3H),3.79(s,3H), 3.21–3.14(m,1H),1.71(p,J=6.6Hz,1H),1.50(h,J=6.9Hz,1H),0.97(t,J=7.0Hz,2H).

[0299] 13 C NMR (125MHz, DMSO-d6) δ160.81,150.60,150.29,149.34,147.26,143.57,139.48,137.12,131.19,130.60,130.33,123.81,122.7 7,121.08,118.23,114.15,111.29,108.24,98.82,69.06,61.81,57.39,56.30,55.65,55.33,36.36,31.06,27.97,19.13,13.74.

[0300] ESI + :544.67.

[0301] Example 39 Synthesis of 3-ethoxy-2,9,10-trimethoxy-13-(3-methylbut-2-en-1-yl)-5,6-dihydroisoquinolino[3,2-a]isoquinolino-7-onium (MX39)

[0302] The experimental procedure was the same as in Example 1, except that the first raw material was 1-bromoethane and the second raw material was 3,3-dimethylallyl bromide; the NMR results of the final product are as follows:

[0303] 1H NMR(500MHz,DMSO-d6)δ9.94(s,1H),7.39(d,J=8.5Hz,1H),7.32(s,1H),7.19(d,J= 8.8Hz,1H),7.02(t,J=1.0Hz,1H),5.31(tp,J=7.2,1.6Hz,1H),4.64(ddd,J=7.3,4. 6,1.7Hz,2H),4.11(q,J=6.3Hz,2H),4.02(s,3H),3.89(d,J=11.0Hz,5H),3.46(dq, J=7.3,1.0Hz,2H),3.21–3.14(m,2H),1.68(q,J=1.2Hz,6H),1.41(t,J=6.2Hz,3H).

[0304] 13 C NMR (125MHz, DMSO-d6) δ150.60,150.30,149.42,147.22,142.90,136.89,130.28,130.17,129.75,128.59,123.77,12 2.75,122.09,121.57,120.78,113.77,111.23,65.18,61.81,58.10,56.30,55.65,28.68,27.97,24.49,19.28,14.60.

[0305] ESI + :434.56.

[0306] Example 40 Synthesis of 2,9,10-trimethoxy-13-(3-methylbut-2-en-1-yl)-3-((4-nitrobenzyl)oxy)-5,6-dihydroisoquinolino[3,2-a]isoquinoline-7-onium (MX40)

[0307] The experimental procedure was the same as in Example 1, except that the first raw material was p-nitrobenzyl bromide and the second raw material was 3,3-dimethylallyl bromide; the NMR results of the final product are as follows:

[0308] 1H NMR (500MHz, DMSO-d6) δ9.94 (s, 1H), 8.14–8.08 (m, 2H), 7.61 (dt, J = 8.2, 1.0Hz, 2H), 7.39 (d ,J=8.5Hz,1H),7.32(s,1H),7.19(d,J=8.8Hz,1H),7.04(t,J=1.1Hz,1H),5.31(dddd,J=9.1, 7.3,3.3,1.6Hz,1H),5.13(t,J=1.1Hz,2H),4.64(ddd,J=7.3,4.6,1.7Hz,2H),4.02(s,3H),3 .88(d,J=13.9Hz,5H),3.46(dp,J=7.4,1.1Hz,2H),3.21–3.14(m,2H),1.68(q,J=1.2Hz,6H).

[0309] 13 C NMR (125MHz, DMSO-d6) δ150.60,149.84,149.48,148.25,147.22,142.90,141.05,136.89,130.41,130.17,129.75,128.68,128.59 ,123.77,123.65,122.76,122.09,121.57,120.78,114.29,111.38,71.39,61.81,58.10,56.30,55.65,28.68,27.97,24.49,19.28.

[0310] ESI + :541.6.

[0311] Example 41 Synthesis of (E)-13-(but-2-en-1-yl)-3-butoxy-2,9,10-trimethoxy-5,6-dihydroisoquinolino[3,2-a]isoquinolino-7-onium (MX41)

[0312] The experimental procedure was the same as in Example 1, except that the first raw material was 1-bromobutane and the second raw material was crotonyl bromide; the NMR results of the final product are as follows:

[0313] 1H NMR(500MHz,DMSO-d6)δ9.94(s,1H),7.39(d,J=8.5Hz,1H),7.32(s,1H),7.19(d,J=8.8Hz,1H) ,7.01(t,J=1.1Hz,1H),5.88–5.78(m,1H),5.72–5.62(m,1H),4.64(ddd,J=7.3,4.6,1.7Hz,2H ),4.07–4.01(m,5H),3.89(d,J=11.0Hz,5H),3.43(dp,J=7.1,1.1Hz,2H),3.21–3.14(m,2H),1 .71(p,J=6.6Hz,2H),1.62(dq,J=5.4,1.1Hz,3H),1.50(h,J=6.9Hz,2H),0.97(t,J=7.0Hz,3H).

[0314] 13 C NMR (125MHz, DMSO-d6) δ150.60,150.29,149.34,147.22,142.92,136.81,130.42,130.21,128.54,128.26,127.61,122.7 8,122.09,121.61,120.78,114.15,111.29,69.06,61.81,58.10,56.30,55.65,33.10,31.06,27.97,19.13,17.90,13.74.

[0315] ESI + :448.25.

[0316] Example 42 Synthesis of 13-(3,5-dimethoxybenzyl)-3-((3,5-dimethoxybenzyl)oxy)-2,9,10-trimethoxy-5,6-dihydroisoquinolino[3,2-a]isoquinoline-7-onium (MX42)

[0317] The experimental procedure was the same as in Example 1, except that both the first and second raw materials were 3,5-dimethoxybenzyl bromide; the NMR results of the final product are as follows:

[0318] 1H NMR(500MHz,DMSO-d6)δ9.94(s,1H),7.37(d,J=8.8Hz,1H),7.32(s,1H),7.19(d,J=8.8Hz, 1H),7.04(t,J=1.0Hz,1H),6.63(dt,J=2.3,1.2Hz,2H),6.46(dt,J=2.1,1.0Hz,2H),6.38(d t,J=12.5,2.4Hz,2H),5.12(t,J=1.0Hz,2H),4.64(ddd,J=7.3,4.6,1.7Hz,2H),4.08(dt,J= 9.5,1.0Hz,1H),4.04–3.97(m,4H),3.88(d,J=13.9Hz,5H),3.79(s,8H),3.21–3.14(m,2H).

[0319] 13 C NMR (125MHz, DMSO-d6) δ160.81,160.51,150.60,149.93,149.48,147.26,143.57,139.48,138.24,137.12,131.19,130.60,130.41,123.8 1,122.75,121.08,118.23,114.29,111.38,108.24,107.23,99.53,9 8.82,71.46,61.81,57.39,56.30,55.65,55.34,55.33,36.36,27.97.

[0320] ESI + :638.28.

[0321] Example 43 Synthesis of 3-((3,5-dimethoxybenzyl)oxy)-2,9,10-trimethoxy-13-(3-methylbut-2-en-1-yl)-5,6-dihydroisoquinolino[3,2-a]isoquinolino-7-onium (MX43)

[0322] The experimental procedure was the same as in Example 1, except that the first raw material was 3,5-dimethoxybenzyl bromide and the second raw material was 3,3-dimethylallyl bromide; the NMR results of the final product are as follows:

[0323] 1H NMR(500MHz,DMSO-d6)δ9.94(s,1H),7.39(d,J=8.5Hz,1H),7.32(s,1H),7.19(d,J=8.8Hz,1H),7 .04(t,J=1.0Hz,1H),6.63(dt,J=2.3,1.2Hz,2H),6.39(t,J=2.4Hz,1H),5.31(dddd,J=9.1,7.3, 3.3,1.6Hz,1H),5.12(t,J=1.0Hz,2H),4.64(ddd,J=7.3,4.6,1.7Hz,2H),4.02(s,3H),3.88(d,J =13.9Hz,5H),3.79(s,5H),3.46(dp,J=7.5,1.1Hz,2H),3.21–3.14(m,2H),1.68(q,J=1.1Hz,6H).

[0324] 13 C NMR (125MHz, DMSO-d6) δ160.51,150.60,149.93,149.48,147.22,142.90,138.24,136.89,130.41,130.17,129.75,128.59,123.77,12 2.76,122.09,121.57,120.78,114.29,111.38,107.23,99.53,71.46,61.81,58.10,56.30,55.65,55.33,28.68,27.97,24.49,19.28.

[0325] ESI + :556.27.

[0326] Example 44 Synthesis of 3-((4-fluorobenzyl)oxy)-2,9,10-trimethoxy-13-(3-methylbut-2-en-1-yl)-5,6-dihydroisoquinolino[3,2-a]isoquinolino-7-onium (MX44)

[0327] The experimental procedure was the same as in Example 1, except that the first raw material was p-chlorobenzyl bromide and the second raw material was p-fluorobenzyl bromide; the NMR results of the final product are as follows:

[0328] 1H NMR(500MHz,DMSO-d6)δ9.94(s,1H),7.37(d,J=8.8Hz,1H),7.34–7.27(m,3H),7.19(d ,J=8.8Hz,1H),7.17(s,1H),7.14(dq,J=7.8,1.2Hz,3H),7.11–7.06(m,2H),7.04(t,J =1.1Hz,1H),5.12(t,J=1.0Hz,2H),4.64(ddd,J=7.3,4.6,1.7Hz,2H),4.19(t,J=1.0H z,2H),4.02(s,2H),3.88(d,J=13.9Hz,5H),3.21–3.14(m,2H),2.34(q,J=0.9Hz,6H).

[0329] 13 C NMR(125MHz,DMSO-d6)δ150.60,149.84,149.48,147.26,143.57,138.34,138.17,137.11,136.95,134.01,131.14,131.00,130.41,129 .27,129.09,128.18,128.03,123.81,122.77,121.08,118.23,114.29,111.38,71.29,61.81,57.39,56.30,55.65,36.00,27.97,21.05.

[0330] ESI + :546.26.

[0331] Example 45 Synthesis of 13-(4-fluorobenzyl)-3-((4-fluorobenzyl)oxy)-2,9,10-trimethoxy-5,6-dihydroisoquinolino[3,2-a]isoquinoline-7-onium (MX45)

[0332] The experimental procedure was the same as in Example 1, except that the first raw material was p-fluorobenzyl bromide and the second raw material was p-fluorobenzyl bromide; the NMR results of the final product are as follows:

[0333] 1H NMR(500MHz,DMSO-d6)δ9.94(s,1H),7.51(ddt,J=8.1,5.1,1.0Hz,2H),7.37(d,J=8.8Hz,1H) ,7.32(s,1H),7.23(ddt,J=7.5,5.0,1.0Hz,2H),7.23–7.14(m,3H),7.17–7.07(m,2H),7.04(t ,J=1.1Hz,1H),5.12(t,J=1.0Hz,2H),4.64(ddd,J=7.3,4.6,1.7Hz,2H),4.41(dt,J=10.0,1.0 Hz,1H),4.20(dt,J=10.0,1.1Hz,1H),4.02(s,3H),3.88(d,J=13.9Hz,5H),3.21–3.14(m,2H).

[0334] 13 C NMR(125MHz,DMSO-d6)δ163.44,163.02,161.42,161.00,150.60,149.84,149.48, 147.26,143.57,137.11,135.51,135.48,132.91,132.89,131.14,131.02,130.41, 129.71,129.64,129.54,129.47,123.81,122.77,121.08,118.23,115.48,115.32,115.26,115.10,114.29,111.38,71.35,61.81,57.39,56.30,55.65,35.83,27.97.

[0335] ESI + :554.21.

[0336] Example 46 Synthesis of 3-((4-fluorobenzyl)oxy)-2,9,10-trimethoxy-13-(3-methylbut-2-en-1-yl)-5,6-dihydroisoquinolino[3,2-a]isoquinolino-7-onium (MX46)

[0337] The experimental procedure was the same as in Example 1, except that the first raw material was p-fluorobenzyl bromide and the second raw material was 3,3-dimethylallyl bromide; the NMR results of the final product are as follows:

[0338] 1H NMR(500MHz,DMSO-d6)δ9.94(s,1H),7.51(ddt,J=8.1,5.1,1.0Hz,2H),7.39(d,J=8.5Hz ,1H),7.32(s,1H),7.21–7.14(m,3H),7.04(t,J=1.1Hz,1H),5.31(dddd,J=9.1,7.3,3.3 ,1.6Hz,1H),5.12(t,J=1.0Hz,2H),4.64(ddd,J=7.3,4.6,1.7Hz,2H),4.02(s,3H),3.88 (d,J=13.9Hz,5H),3.46(dp,J=7.5,1.1Hz,2H),3.21–3.14(m,2H),1.68(q,J=1.2Hz,6H).

[0339] 13 C NMR(125MHz,DMSO-d6)δ163.44,161.42,150.60,149.84,149.48,147.22, 142.90,136.89,132.91,132.89,130.41,130.17,129.75,129.54,129.47 ,128.59,123.77,122.76,122.09,121.57,120.78,115.26,115.10,114.2 9,111.38,71.35,61.81,58.10,56.30,55.65,28.68,27.97,24.49,19.28.

[0340] ESI + :514.24.

[0341] Example 47 Synthesis of 3-(cyanomethoxy)-13-(cyanomethyl)-2,9,10-trimethoxy-5,6-dihydroisoquinolino[3,2-a]isoquinoline-7-onium (MX47)

[0342] The experimental procedure was the same as in Example 1, except that the first raw material was bromoacetonitrile, and the second raw material was bromoacetonitrile; the NMR results of the final product are as follows:

[0343] 1H NMR(500MHz,DMSO-d6)δ9.86(s,1H),7.39(d,J=8.5Hz,1H),7.32(s,1H),7.19(d,J=8.8Hz,1H),7.06(t,J=1.1Hz,1H) ,4.98(s,2H),4.63(ddd,J=7.3,4.6,1.1Hz,2H),4.20(s,2H),4.02(s,3H),3.88(d,J=15.9Hz,5H),3.21–3.14(m,2H).

[0344] 13 C NMR (125MHz, DMSO-d6) δ150.60,149.15,148.42,147.41,142.69,136.13,130.32,128.89,127.79,122.42, 122.02,121.43,120.80,117.11,116.24,114.54,111.57,61.81,58.16,56.30,55.66,54.47,27.97,18.88.

[0345] ESI + :416.16.

[0346] Example 48 Synthesis of 2,9,10-trimethoxy-13-(prop-2-yn-1-yl)-3-(prop-2-yn-1-yloxy)-5,6-dihydroisoquino[3,2-a]isoquinoline-7-onium (MX48)

[0347] The experimental procedure was the same as in Example 1, except that the first raw material was 3-bromopropyne and the second raw material was 3-bromopropyne; the NMR results of the final product are as follows:

[0348] 1 H NMR (500MHz, DMSO-d6) δ9.86 (s, 1H), 7.39 (d, J = 8.5Hz, 1H), 7.32 (s, 1H), 7.19 (d,J=8.8Hz,1H),7.06(t,J=1.0Hz,1H),4.82(d,J=2.9Hz,2H),4.74(d,J=2.9H z,2H),4.63(ddd,J=7.3,4.6,1.1Hz,2H),4.02(s,3H),3.88(d,J=15.9Hz,5H) ,3.36(s,1H),3.36(d,J=6.1Hz,1H),3.21–3.14(m,2H),2.69(t,J=2.9Hz,1H).

[0349] 13 C NMR (125MHz, DMSO-d6) δ150.60,149.16,149.12,147.29,142.49,136.86,130.33,130.18,129.40,122.68,122.0 0,121.29,120.79,114.53,111.57,83.55,78.41,76.70,72.39,61.81,58.28,58.16,56.30,55.66,27.97,21.95.

[0350] ESI + :414.17.

[0351] Example 49 Synthesis of 2,9,10-trimethoxy-13-(3-methylbut-2-en-1-yl)-3-(ethoxy)-5,6-dihydroisoquinolino[3,2-a]isoquinolino-7-onium (MX49)

[0352] The experimental procedure was the same as in Example 1, except that the first raw material was ethylene bromide and the second raw material was 3,3-dimethylallyl bromide; the NMR results of the final product are as follows:

[0353] 1 H NMR (500MHz, DMSO-d6) δ9.94(s,1H),7.53(s,1H),7.39(d,J=8.5Hz,1H),7.19(d,J=8.8Hz,1H),7. 03(t,J=1.0Hz,1H),6.70(s,1H),5.31(dddd,J=9.1,7.3,3.3,1.6Hz,1H),4.68(dd,J=9.9,2.8Hz,1 H),4.64(ddd,J=7.3,4.6,1.7Hz,2H),4.27(dd,J=9.9,2.8Hz,1H),4.02(s,3H),3.88(d,J=17.1Hz ,5H),3.46(dp,J=7.4,1.1Hz,2H),3.24(dddd,J=15.9,7.6,4.6,1.0Hz,2H),1.68(q,J=1.2Hz,6H).

[0354] 13C NMR(125MHz,DMSO-d6)δ150.60,149.09,148.05,147.22,147.00,142.90,136.89,131.64,130.17,129.75,128.59,123 .77,123.67,122.09,121.57,120.78,116.05,110.64,93.31,61.81,58.15,56.30,56.11,28.68,27.55,24.49,19.28.

[0355] ESI + :436.25.

[0356] Example 50 Synthesis of 2,9,10-trimethoxy-13-(3-nitrobenzyl)-3-((3-nitrobenzyl)oxy)-5,6-dihydroisoquinolino[3,2-a]isoquinoline-7-onium (MX50)

[0357] The experimental procedure was the same as in Example 1, except that both the first and second raw materials were m-nitrobenzyl bromide; the NMR results of the final product are as follows:

[0358] 1 H NMR(500MHz,DMSO-d6)δ9.94(s,1H),8.29(tt,J=2.2,1.0Hz,1H),8.20–8.13(m,2H),8.12(tt,J=2.1,1.0Hz,1H), 7.72(ddq,J=8.0,2.3,1.2Hz,1H),7.60(ddd,J=12.3,8.8,7.8Hz,2H),7.53–7.47(m,1H),7.37(d,J=8.8Hz,1H),7 .32(s,1H),7.19(d,J=8.8Hz,1H),7.04(t,J=1.0Hz,1H),5.24(t,J=1.0Hz,2H),4.64(ddd,J=7.3,4.6,1.7Hz,2H) ,4.50(dt,J=9.8,1.0Hz,1H),4.08(dt,J=9.8,1.0Hz,1H),4.02(s,3H),3.88(d,J=13.9Hz,5H),3.21–3.14(m,2H).

[0359] 13C NMR(125MHz,DMSO-d6)δ150.60,149.86,149.48,148.45,148.32,147.26, 143.57,138.07,137.12,137.02,133.52,133.35,131.19,131.09,130.41, 129.50,129.26,124.37,124.14,123.81,123.79,123.36,122.75,121.08, 118.23,114.29,111.38,71.22,61.81,57.39,56.30,55.65,36.55,27.97.

[0360] ESI + :608.20.

[0361] Example 51 Synthesis of 13-(4-fluorobenzyl)-2,9,10-trimethoxy-3-(pent-4-yn-1-yloxy)-5,6-dihydroisoquino[3,2-a]isoquinoline-7-onium (MX51)

[0362] The experimental procedure was the same as in Example 1, except that the first raw material was 1-bromopentyne and the second raw material was p-fluorobenzyl bromide; the NMR results of the final product are as follows:

[0363] 1 H NMR(500MHz,DMSO-d6)δ9.94(s,1H),7.37(d,J=8.8Hz,1H),7.32(s,1H),7.23(ddt,J=7.5,5.0,1.0Hz,2 H),7.19(d,J=8.8Hz,1H),7.15–7.07(m,2H),7.01(t,J=1.0Hz,1H),4.64(ddd,J=7.3,4.6,1.7Hz,2H),4. 41(dt,J=10.0,1.0Hz,1H),4.20(dt,J=10.0,1.1Hz,1H),4.14(t,J=6.1Hz,2H),4.02(s,3H),3.89(d,J=1 1.0Hz,5H),3.21–3.14(m,2H),2.57(td,J=6.3,3.0Hz,2H),2.07(t,J=2.9Hz,1H),1.95(p,J=6.3Hz,2H).

[0364] 13C NMR(125MHz,DMSO-d6)δ163.02,161.00,150.60,150.45,149.39,147.26 ,143.57,137.11,135.51,135.48,131.14,131.02,130.33,129.71,129.6 4,123.81,122.77,121.08,118.23,115.48,115.32,114.15,111.29,83.6 4,69.24,68.63,61.81,57.39,56.30,55.65,35.83,28.27,27.97,15.64.

[0365] ESI + :512.6.

[0366] Example 52 Synthesis of 3-(4-cyanobutoxy)-13-(6-cyanohexyl)-2,9,10-trimethoxy-5,6-dihydroisoquino[3,2-a]isoquinoline-7-onium (MX52)

[0367] The experimental procedure was the same as in Example 1, except that the first raw material was 1-bromohexanonitrile and the second raw material was 1-bromooctanonitrile; the NMR results of the final product are as follows:

[0368] 1 H NMR (500MHz, DMSO-d6) δ7.32(d,J=8.0Hz,1H),7.01(t,J=1.1Hz,0H),4.63(ddd,J=7.6,4.9,1.2Hz,1H),4.08(t,J=5.0Hz,1H),4.02(s,1 H),3.89(d,J=11.0Hz,2H),3.21–3.14(m,1H),2.78(t,J=8.5Hz,1H),2.40(dt,J=17.4,5.8Hz,2H),1.82–1.60(m,4H),1.44–1.33(m,2H).

[0369] 13C NMR(125MHz,DMSO-d6)δ150.63,150.37,149.34,146.81,143.03,137.45,135.26,133.19,130.22,123.25,122.15,121.99,121.50, 119.41,114.15,111.29,69.22,61.81,58.81,56.30,55.65,30.56,28.81,28.61,28.57,28.27,27.97,25.62,22.12,17.12,16.76.

[0370] ESI + :528.29.

[0371] Example 53 Synthesis of 13-(6-cyanohexyl)-3-((5-cyanopentyl)oxy)-2,9,10-trimethoxy-5,6-dihydroisoquinolino[3,2-a]isoquinoline-7-onium (MX53)

[0372] The experimental procedure was the same as in Example 1, except that the first raw material was 1-bromoheptanenitrile, and the second raw material was 1-bromooctanenitrile; the NMR results of the final product are as follows:

[0373] 1 H NMR(500MHz,DMSO-d6)δ7.32(d,J=8.0Hz,1H),7.01(t,J=1.0Hz,0H),4.63(ddd ,J=7.6,4.9,1.2Hz,1H),4.04–3.97(m,2H),3.89(d,J=11.0Hz,2H),3.21–3.14 (m,1H),2.78(t,J=8.5Hz,1H),2.38(td,J=5.9,3.0Hz,2H),1.78–1.69(m,1H), 1.71–1.64(m,2H),1.67–1.60(m,1H),1.49(p,J=6.3Hz,1H),1.44–1.33(m,2H).

[0374] 13C NMR (125MHz, DMSO-d6) δ150.63,150.29,149.34,146.81,143.03,137.45,135.26,133.19,130.27,123.25,122.15,121.99,121.50,119 .41,114.15,111.29,68.80,61.81,58.81,56.30,55.65,30.56,29.15,28.81,28.61,28.27,27.97,25.62,25.52,24.65,17.12,17.06.

[0375] ESI + :542.3.

[0376] Example 54 Synthesis of 13-(4-cyanobutyl)-3-((6-cyanohexyl)oxy)-2,9,10-trimethoxy-5,6-dihydroisoquinolino[3,2-a]isoquinoline-7-onium (MX54)

[0377] The experimental procedure was the same as in Example 1, except that the first raw material was 1-bromooctanilide and the second raw material was 1-bromohexanilide; the NMR results of the final product are as follows:

[0378] 1 H NMR (500MHz, DMSO-d6) δ7.32(d,J=8.0Hz,1H),7.01(t,J=1.1Hz,0H),4.63(ddd,J=7.6,4.9,1.2Hz,1H),4.04–3.97(m,2H),3.89(d,J=11. 0Hz,2H),3.21–3.14(m,1H),2.87–2.69(m,1H),2.39(dt,J=7.8,5.9Hz,2H),1.82–1.69(m,3H),1.64(p,J=5.9Hz,1H),1.50–1.35(m,2H).

[0379] 13C NMR(125MHz,DMSO-d6)δ150.63,150.29,149.34,146.82,143.03,137.46,134.72,133.19,130.22,123.25,122.15,121.99,121.50, 119.41,114.15,111.29,68.80,61.81,58.81,56.30,55.65,30.58,29.33,28.14,27.97,27.43,26.07,25.60,24.40,17.12,16.92.

[0380] ESI + :528.29.

[0381] Example 55 Synthesis of 13-(5-cyanopentyl)-2,9,10-trimethoxy-3-((3-methylbut-2-en-1-yl)oxy)-5,6-dihydroisoquinolino[3,2-a]isoquinoline-7-onium (MX55)

[0382] The experimental procedure was the same as in Example 1, except that the first raw material was 3,3-dimethylallyl bromide and the second raw material was 1-bromoheptanenitrile; the NMR results of the final product are as follows:

[0383] 1 H NMR(500MHz,DMSO-d6)δ9.94(s,0H),7.32(d,J=8.5Hz,0H),6.99(t,J=1.1H z,0H),5.28(ddp,J=6.5,3.1,1.6Hz,0H),4.67–4.59(m,2H),4.02(s,1H),3 .88(d,J=13.9Hz,2H),3.21–3.14(m,1H),2.78(t,J=8.5Hz,1H),2.38(t,J= 5.9Hz,1H),1.81–1.72(m,4H),1.67(p,J=5.8Hz,1H),1.38(p,J=6.1Hz,1H).

[0384] 13C NMR(125MHz,DMSO-d6)δ150.63,150.34,149.25,146.81,143.03,137.69,137.45,135.28,133.19,130.25,123.25,122.15,121.99,1 21.50,119.41,119.22,113.80,111.34,66.09,61.81,58.81,56.30,55.65,30.60,28.64,27.97,27.89,24.80,24.62,19.90,17.06.

[0385] ESI + :501.28.

[0386] Example 56 Synthesis of 3-((5-cyanopentyl)oxy)-2,9,10-trimethoxy-13-(3-methylbut-2-en-1-yl)-5,6-dihydroisoquinolino[3,2-a]isoquinolino-7-onium (MX56)

[0387] The experimental procedure was the same as in Example 1, except that the first raw material was 1-bromoheptanenitrile and the second raw material was 3,3-dimethylallyl bromide; the NMR results of the final product are as follows:

[0388] 1 H NMR(500MHz,DMSO-d6)δ9.94(s,1H),7.39(d,J=8.5Hz,1H),7.32(s,1H),7.19(d,J=8.8Hz,1 H),7.01(t,J=1.0Hz,1H),5.31(dddd,J=9.1,7.2,3.3,1.6Hz,1H),4.64(dddd,J=7.3,4.6,1.7 Hz,2H),4.04–3.97(m,5H),3.89(d,J=11.0Hz,5H),3.46(dp,J=7.5,1.1Hz,2H),3.21–3.14(m ,2H),2.39(t,J=5.9Hz,2H),1.74(p,J=6.2Hz,2H),1.71–1.63(m,8H),1.49(p,J=6.3Hz,2H).

[0389] 13C NMR(125MHz,DMSO-d6)δ150.60,150.29,149.34,147.22,142.90,136.89,130.31,130.17,129.75,128.59,123.77,122.74,122.09,1 21.57,120.78,119.41,114.15,111.29,68.80,61.81,58.10,56.30,55.65,29.15,28.68,27.97,25.52,24.65,24.49,19.28,17.06.

[0390] ESI + :501.28.

[0391] Example 57: Inhibitory activity of the compound against colon cancer cells

[0392] Compounds MX1-MX56, prepared using Examples 1-56, were co-incubated with colon cancer cell lines SW620, DLD-1, and SW480, and gastric cancer AGS cells, respectively. The compound concentrations were 1 μM, 2 μM, 4 μM, 8 μM, 16 μM, 32 μM, 64 μM, and 128 μM, and the cell concentration was 1*10^4 cells / well. Co-incubation with the compounds was performed for 24 h. The half-maximal inhibitory concentration (TC50) of the compounds against cells was determined in vitro using a CCK-8 assay. The results are shown in Table 1.

[0393] Table 1

[0394] The above results indicate that the compound MX1-MX56 provided in this application has better inhibitory activity against colon cancer cell proliferation and gastric cancer cell proliferation than BBR.

[0395] The inhibitory activity of compound MX51 against three types of colon cancer cells is shown below only with the aid of accompanying figures.

[0396] Figure 1 shows the inhibitory effect of compound MX51 on the proliferation of three colon cancer cell lines SW620, DLD-1 and SW480 by CCK-8 assay in vitro. The IC50 values ​​were 11.75 μM, 8.62 μM and 13.96 μM, respectively (AC in Figure 1), indicating that the compound has better inhibitory activity on colon cancer cell proliferation than BBR.

[0397] Example 58: Compound Inhibits Colon Cancer Tumor Growth

[0398] The inhibitory effects of the compounds in this application on the development and progression of colon cancer were evaluated in subcutaneous tumor models, orthotopic cecal inoculation models, and AOM / DSS spontaneous colon cancer models. Mice were acclimatized for one week, then 5-6 weeks old mice were intraperitoneally injected with azomethane (AOM) (10 mg / mL) followed by a week of feeding with standard drinking water. This was followed by a week of feeding with 2.5% DSS, then another week of feeding with standard drinking water. This process was repeated 2-3 times to induce spontaneous colon cancer in mice.

[0399] Taking MX51 as an example, 1*10^6 SW620 cells were subcutaneously inoculated into immunodeficient mice, and tumor volume was measured and recorded 7 days later. The results are shown in Figure 2. It was found that the tumors in the MX51 treatment group (10 mg / kg) were significantly improved in terms of both tumor volume and tumor weight, suggesting that it can significantly inhibit tumor growth in vivo (CTRL is the control group without compound treatment).

[0400] By inoculating 1*10^6 SW620 cells into the cecum of immunodeficient mice, as shown in Figure 3, it was found that treatment with MX51 (10 mg / kg) could significantly inhibit the growth of SW620 tumors in the cecum, reduce the size of cecal tumors, and at the same time, MX51 treatment could significantly inhibit the occurrence of liver metastasis of tumor cells (Figure 3A) and prolong the survival of the tumor-bearing mice.

[0401] Example 59

[0402] Five- to six-week-old mice were injected intraperitoneally with azomethane (AOM) (10 mg / mL) and fed with regular drinking water for one week. Then, they were fed with 2.5% DSS for one week, followed by regular drinking water for two weeks. This process was repeated two to three times to induce spontaneous colon cancer in mice.

[0403] In this model, MX51 was administered (10 mg / kg), and the results are shown in Figure 4. The results show that MX51 treatment had no effect on the body weight of mice, indicating that MX51 has good safety in vivo. At the same time, it was found that MX51 can significantly reduce the number of tumors, prolong the length of the entire cecum, reduce the degree of damage to the intestinal mucosal barrier, and prolong the survival of mice.

[0404] In the description of this specification, the references to terms such as "one embodiment," "some embodiments," "example," "specific example," "some implementations," or "some examples," etc., refer to specific features, structures, materials, or characteristics described in connection with that embodiment or example, which are included in at least one embodiment or example of this application. In this specification, the illustrative expressions of the above terms do not necessarily refer to the same embodiment or example. Furthermore, the specific features, structures, materials, or characteristics described may be combined in any suitable manner in one or more embodiments or examples. Moreover, without contradiction, those skilled in the art can combine and integrate the different embodiments or examples described in this specification, as well as the features of different embodiments or examples.

[0405] Although embodiments of this application have been shown and described above, it is understood that the above embodiments are exemplary and should not be construed as limiting this application. Those skilled in the art can make changes, modifications, substitutions and variations to the above embodiments within the scope of this application.

Claims

1. A compound, said compound being a compound of general formula (I) or a pharmaceutically acceptable salt of a compound of general formula (I): in, R1 and R2 are each independently selected from -(CH2)mR3, -(CH2)n-CN, unsubstituted C2-C10 alkenyl, unsubstituted C2-C10 alkynyl, and C1-C10 alkyl substituted with at least one -NH2; m = 1, n = 1 to 10; R3 is an unsubstituted or phenyl group substituted with at least one Rb; Rb is selected from -NO2, halogens, C1 alkoxy groups, and C1 alkyl groups. In this case, R1 and R2 are not both C3 or C4 alkenyl groups.

2. The compound according to claim 1, wherein the compound is selected from one of the following structures:

3. A pharmaceutical composition comprising the compound of claim 1.

4. A pharmaceutical composition comprising the compound of claim 2.

5. Use of the compound of claim 1 in the preparation of a medicament for treating gastrointestinal tumors, wherein the gastrointestinal tumor is colon cancer or gastric cancer.

6. Use of the compound of claim 2 in the preparation of a medicament for treating gastrointestinal tumors, wherein the gastrointestinal tumor is colon cancer or gastric cancer.